{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:15:40Z","timestamp":1783062940758,"version":"3.54.6"},"reference-count":304,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007241","name":"Universit\u00e9 Paris-Saclay","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007241","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"abstract":"Abstract<\/jats:title>\n \n Purpose of Review<\/jats:title>\n Locoregional therapies have emerged as key components in the therapeutic arsenal against gastrointestinal cancers, offering minimally invasive options with curative potential. Beyond their direct cytotoxic effects, these interventions can remodel the tumour microenvironment by inducing immunogenic cell death and initiating local and systemic immune responses, including abscopal effects. This review aims to examine how these immunomodulatory properties may support locoregional therapies as an ideal platform for intratumoural immunotherapy, positioning their combination at the core of the evolving field of interventional immuno-oncology.<\/jats:p>\n <\/jats:sec>\n \n Recent Findings<\/jats:title>\n Recent studies demonstrate that locoregional therapies can induce immune responses through modulation of the tumour microenvironment, creating conditions that may be exploited by intratumoural immunotherapy. This review provides a comprehensive overview of current locoregional modalities, including thermal and non-thermal ablative techniques, transarterial therapies, and minimally invasive radiation methods, detailing their mechanisms of action, clinical applications, and immune-related effects. Special attention is given to emerging evidence supporting the combination of these approaches with intratumoural delivery of immunomodulatory agents, to enhance anticancer immune responses.<\/jats:p>\n <\/jats:sec>\n \n Summary<\/jats:title>\n The convergence of locoregional intervention and targeted immunomodulation represents an emerging therapeutic concept in the treatment of gastrointestinal cancers, offering the prospect of personalised, tumour-directed immune activation. This approach holds the potential to extend the benefits of immunotherapy beyond genetically defined subgroups to a broader patient population.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s11912-026-01807-1","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:18:31Z","timestamp":1783059511000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting the Immunological Landscape of Locoregional Therapies for Gastrointestinal Cancers: A Shift Toward Interventional Immuno-Oncology"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-3407-9313","authenticated-orcid":false,"given":"Augustin","family":"Suffisseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5689-7046","authenticated-orcid":false,"given":"Johanne","family":"Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7222-6151","authenticated-orcid":false,"given":"Katia","family":"Lemdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Diakhaby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Capron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8370-8754","authenticated-orcid":false,"given":"Mostafa","family":"El Hajjam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Peschaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3323-2997","authenticated-orcid":false,"given":"Nathalie","family":"Mignet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6492-5286","authenticated-orcid":false,"given":"Robert","family":"Malafosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1807_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"1807_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.dld.2022.07.008","volume":"54","author":"C Coutzac","year":"2022","unstructured":"Coutzac C, Bibeau F, Ben Abdelghani M, Aparicio T, Cohen R, Coquan E, et al. Immunotherapy in MSI\/dMMR tumors in the perioperative setting: The IMHOTEP trial. Dig Liver Dis. 2022;54:1335\u201341. https:\/\/doi.org\/10.1016\/j.dld.2022.07.008.","journal-title":"Dig Liver Dis"},{"key":"1807_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.26355\/eurrev_202001_20058","volume":"24","author":"B Fionda","year":"2020","unstructured":"Fionda B, Massaccesi M, Tagliaferri L, Dinapoli N, Iezzi R, Boldrini L. Abscopal effect and interventional oncology: state of art and future perspectives. Eur Rev Med Pharmacol Sci. 2020;24:773\u20136. https:\/\/doi.org\/10.26355\/eurrev_202001_20058.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1807_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.immuni.2013.06.014","volume":"39","author":"L Zitvogel","year":"2013","unstructured":"Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance. Immunity. 2013;39:74\u201388. https:\/\/doi.org\/10.1016\/j.immuni.2013.06.014.","journal-title":"Immunity"},{"key":"1807_CR5","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.1016\/j.jvir.2010.04.008","volume":"21","author":"K Hong","year":"2010","unstructured":"Hong K, Georgiades C. Radiofrequency Ablation: Mechanism of Action and Devices. J Vasc Interv Radiol. 2010;21:S179\u201386. https:\/\/doi.org\/10.1016\/j.jvir.2010.04.008.","journal-title":"J Vasc Interv Radiol"},{"key":"1807_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/9251375","volume":"2016","author":"A Mehta","year":"2016","unstructured":"Mehta A, Oklu R, Sheth RA. Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? Gastroenterol Res Pract. 2016;2016:1\u201311. https:\/\/doi.org\/10.1155\/2016\/9251375.","journal-title":"Gastroenterol Res Pract"},{"key":"1807_CR7","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1038\/srep07252","volume":"4","author":"Q Xu","year":"2014","unstructured":"Xu Q, Kobayashi S, Ye X, Meng X. Comparison of Hepatic Resection and Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Meta-Analysis of 16,103 Patients. Sci Rep. 2014;4:7252. https:\/\/doi.org\/10.1038\/srep07252.","journal-title":"Sci Rep"},{"key":"1807_CR8","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3393\/jksc.2011.27.4.202","volume":"27","author":"JH Gwak","year":"2011","unstructured":"Gwak JH, Oh B-Y, Lee RA, Chung SS, Kim KH. Clinical Applications of Radio-Frequency Ablation in Liver Metastasis of Colorectal Cancer. J Korean Soc Coloproctology. 2011;27:202. https:\/\/doi.org\/10.3393\/jksc.2011.27.4.202.","journal-title":"J Korean Soc Coloproctology"},{"key":"1807_CR9","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.5009\/gnl.2010.4.S1.S113","volume":"4","author":"H Rhim","year":"2010","unstructured":"Rhim H, Lim HK. Radiofrequency Ablation of Hepatocellular Carcinoma: Pros and Cons. Gut Liver. 2010;4:S113. https:\/\/doi.org\/10.5009\/gnl.2010.4.S1.S113.","journal-title":"Gut Liver"},{"key":"1807_CR10","doi-asserted-by":"publisher","first-page":"101590","DOI":"10.1016\/j.clinre.2020.101590","volume":"45","author":"JF Blanc","year":"2021","unstructured":"Blanc JF, Debaillon-Vesque A, Roth G, Barbare JC, Baumann AS, Boige V, et al. Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR\/FRI). Clin Res Hepatol Gastroenterol. 2021;45:101590. https:\/\/doi.org\/10.1016\/j.clinre.2020.101590.","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"1807_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/01.sla.0000201480.65519.b8","volume":"243","author":"M-S Chen","year":"2006","unstructured":"Chen M-S, Li J-Q, Zheng Y, Guo R-P, Liang H-H, Zhang Y-Q, et al. A Prospective Randomized Trial Comparing Percutaneous Local Ablative Therapy and Partial Hepatectomy for Small Hepatocellular Carcinoma. Ann Surg. 2006;243:321\u20138. https:\/\/doi.org\/10.1097\/01.sla.0000201480.65519.b8.","journal-title":"Ann Surg"},{"key":"1807_CR12","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1097\/SLA.0b013e3181efc656","volume":"252","author":"J Huang","year":"2010","unstructured":"Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al. A Randomized Trial Comparing Radiofrequency Ablation and Surgical Resection for HCC Conforming to the Milan Criteria. Ann Surg. 2010;252:903\u201312. https:\/\/doi.org\/10.1097\/SLA.0b013e3181efc656.","journal-title":"Ann Surg"},{"key":"1807_CR13","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jhep.2012.05.007","volume":"57","author":"K Feng","year":"2012","unstructured":"Feng K, Yan J, Li X, Xia F, Ma K, Wang S, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012;57:794\u2013802. https:\/\/doi.org\/10.1016\/j.jhep.2012.05.007.","journal-title":"J Hepatol"},{"key":"1807_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/jgh.12441","volume":"29","author":"Y Fang","year":"2014","unstructured":"Fang Y, Chen W, Liang X, Li D, Lou H, Chen R, et al. Comparison of long-term effectiveness and complications of radiofrequency ablation with hepatectomy for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:193\u2013200. https:\/\/doi.org\/10.1111\/jgh.12441.","journal-title":"J Gastroenterol Hepatol"},{"key":"1807_CR15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/bjs.10061","volume":"103","author":"H Liu","year":"2016","unstructured":"Liu H, Wang Z-G, Fu S-Y, Li A-J, Pan Z-Y, Zhou W-P, et al. Randomized clinical trial of chemoembolization plus radiofrequency ablation versus partial hepatectomy for hepatocellular carcinoma within the Milan criteria. Br J Surg. 2016;103:348\u201356. https:\/\/doi.org\/10.1002\/bjs.10061.","journal-title":"Br J Surg"},{"key":"1807_CR16","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1148\/radiol.11110817","volume":"262","author":"Z-W Peng","year":"2012","unstructured":"Peng Z-W, Lin X-J, Zhang Y-J, Liang H-H, Guo R-P, Shi M, et al. Radiofrequency Ablation versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas 2\u00a0cm or Smaller: A Retrospective Comparative Study. Radiology. 2012;262:1022\u201333. https:\/\/doi.org\/10.1148\/radiol.11110817.","journal-title":"Radiology"},{"key":"1807_CR17","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/MEG.0000000000000012","volume":"26","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Lei J, Li B, Yan L, Wang W, Wei Y, et al. Liver resection and radiofrequency ablation of very early hepatocellular carcinoma cases (single nodule\u2009<\u20092\u00a0cm): a single-center study. Eur J Gastroenterol Hepatol. 2014;26:339\u201344. https:\/\/doi.org\/10.1097\/MEG.0000000000000012.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1807_CR18","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/bjs.9960","volume":"103","author":"G-A Kim","year":"2015","unstructured":"Kim G-A, Shim JH, Kim M-J, Kim SY, Won HJ, Shin YM, et al. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. Br J Surg. 2015;103:126\u201335. https:\/\/doi.org\/10.1002\/bjs.9960.","journal-title":"Br J Surg"},{"key":"1807_CR19","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/SLA.0000000000001178","volume":"263","author":"P-H Liu","year":"2016","unstructured":"Liu P-H, Hsu C-Y, Hsia C-Y, Lee Y-H, Huang Y-H, Chiou Y-Y, et al. Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma\u2009\u2264\u20092\u00a0cm in a Propensity Score Model. Ann Surg. 2016;263:538\u201345. https:\/\/doi.org\/10.1097\/SLA.0000000000001178.","journal-title":"Ann Surg"},{"key":"1807_CR20","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1007\/s11605-015-2850-z","volume":"19","author":"X Xie","year":"2015","unstructured":"Xie X, Jiang C, Peng Z, Liu B, Hu W, Wang Y, et al. Local Recurrence after Radiofrequency Ablation of Hepatocellular Carcinoma: Treatment Choice and Outcome. J Gastrointest Surg. 2015;19:1466\u201375. https:\/\/doi.org\/10.1007\/s11605-015-2850-z.","journal-title":"J Gastrointest Surg"},{"key":"1807_CR21","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.dld.2019.05.035","volume":"51","author":"JM Phelip","year":"2019","unstructured":"Phelip JM, Tougeron D, L\u00e9onard D, Benhaim L, Desolneux G, Dupr\u00e9 A, et al. Metastatic colorectal cancer (mCRC): French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR). Dig Liver Dis. 2019;51:1357\u201363. https:\/\/doi.org\/10.1016\/j.dld.2019.05.035.","journal-title":"Dig Liver Dis"},{"key":"1807_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006317.pub3","author":"R Cirocchi","year":"2012","unstructured":"Cirocchi R, Trastulli S, Boselli C, Montedori A, Cavaliere D, Parisi A, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2012. https:\/\/doi.org\/10.1002\/14651858.CD006317.pub3. CD006317.","journal-title":"Cochrane Database Syst Rev"},{"key":"1807_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11604-012-0089-0","volume":"30","author":"A Hamada","year":"2012","unstructured":"Hamada A, Yamakado K, Nakatsuka A, Uraki J, Kashima M, Takaki H, et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol. 2012;30:567\u201374. https:\/\/doi.org\/10.1007\/s11604-012-0089-0.","journal-title":"Jpn J Radiol"},{"key":"1807_CR24","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1007\/s00330-015-3779-z","volume":"25","author":"A Gillams","year":"2015","unstructured":"Gillams A, Goldberg N, Ahmed M, Bale R, Breen D, Callstrom M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans fronti\u00e8res meeting 2013. Eur Radiol. 2015;25:3438\u201354. https:\/\/doi.org\/10.1007\/s00330-015-3779-z.","journal-title":"Eur Radiol"},{"key":"1807_CR25","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.hpb.2017.08.023","volume":"20","author":"L Benhaim","year":"2018","unstructured":"Benhaim L, El Hajjam M, Malafosse R, Sellier J, Julie C, Beauchet A, et al. Radiofrequency ablation for colorectal cancer liver metastases initially greater than 25\u00a0mm but downsized by neo-adjuvant chemotherapy is associated with increased rate of local tumor progression. HPB. 2018;20:76\u201382. https:\/\/doi.org\/10.1016\/j.hpb.2017.08.023.","journal-title":"HPB"},{"key":"1807_CR26","doi-asserted-by":"publisher","DOI":"10.4293\/JSLS.2022.00070","volume":"26","author":"Y Hamzaoui","year":"2022","unstructured":"Hamzaoui Y, Genova P, Peschaud F, Malafosse R, El Hajjam M, Lupinacci RM. Safeness of simultaneous colonic resection and hepatic radiofrequency ablation. JSLS. 2022;26:e2022.00070. https:\/\/doi.org\/10.4293\/JSLS.2022.00070.","journal-title":"JSLS"},{"key":"1807_CR27","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S1470-2045(24)00660-0","volume":"26","author":"S Van Der Lei","year":"2025","unstructured":"Van Der Lei S, Puijk RS, Dijkstra M, Schulz HH, Vos DJW, De Vries JJJ, et al. Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial. Lancet Oncol. 2025;26:187\u201399. https:\/\/doi.org\/10.1016\/S1470-2045(24)00660-0.","journal-title":"Lancet Oncol"},{"key":"1807_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx015","author":"T Ruers","year":"2017","unstructured":"Ruers T, Van Coevorden F, Punt CJA, Pierie J-PEN, Borel-Rinkes I, Ledermann JA, et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. JNCI J Natl Cancer Inst [Internet]. 2017. https:\/\/doi.org\/10.1093\/jnci\/djx015. [cited 2025 Aug 18];109.","journal-title":"JNCI J Natl Cancer Inst [Internet]"},{"key":"1807_CR29","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1002\/cncr.25958","volume":"117","author":"EM Von Meyenfeldt","year":"2011","unstructured":"Von Meyenfeldt EM, Prevoo W, Peyrot D, Fat NLA, Burgers SJA, Wouters MW, et al. Local progression after radiofrequency ablation for pulmonary metastases. Cancer. 2011;117:3781\u20137. https:\/\/doi.org\/10.1002\/cncr.25958.","journal-title":"Cancer"},{"key":"1807_CR30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.21037\/tgh.2019.08.03","volume":"4","author":"A Guner","year":"2019","unstructured":"Guner A, Yildirim R. Surgical management of metastatic gastric cancer: moving beyond the guidelines. Transl Gastroenterol Hepatol. 2019;4:58. https:\/\/doi.org\/10.21037\/tgh.2019.08.03.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"1807_CR31","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1001\/jamaoncol.2017.0515","volume":"3","author":"S-E Al-Batran","year":"2017","unstructured":"Al-Batran S-E, Homann N, Pauligk C, Illerhaus G, Martens UM, Stoehlmacher J, et al. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol. 2017;3:1237. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0515.","journal-title":"JAMA Oncol"},{"key":"1807_CR32","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1186\/s12885-017-3918-9","volume":"17","author":"S-E Al-Batran","year":"2017","unstructured":"Al-Batran S-E, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction \u2013 a phase III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer. 2017;17:893. https:\/\/doi.org\/10.1186\/s12885-017-3918-9.","journal-title":"BMC Cancer"},{"key":"1807_CR33","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12885-017-3156-1","volume":"17","author":"JW Lee","year":"2017","unstructured":"Lee JW, Choi MH, Lee YJ, Ali B, Yoo HM, Song KY, et al. Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection. BMC Cancer. 2017;17:185. https:\/\/doi.org\/10.1186\/s12885-017-3156-1.","journal-title":"BMC Cancer"},{"key":"1807_CR34","doi-asserted-by":"publisher","first-page":"030006052094050","DOI":"10.1177\/0300060520940509","volume":"48","author":"K Tang","year":"2020","unstructured":"Tang K, Zhang B, Dong L, Wang L, Tang Z. Radiofrequency ablation versus traditional liver resection and chemotherapy for liver metastases from gastric cancer. J Int Med Res. 2020;48:030006052094050. https:\/\/doi.org\/10.1177\/0300060520940509.","journal-title":"J Int Med Res"},{"key":"1807_CR35","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/gutjnl-2020-322082","volume":"70","author":"M Barret","year":"2021","unstructured":"Barret M, Pioche M, Terris B, Ponchon T, Cholet F, Zerbib F, et al. Endoscopic radiofrequency ablation or surveillance in patients with Barrett\u2019s oesophagus with confirmed low-grade dysplasia: a multicentre randomised trial. Gut. 2021;70:1014\u201322. https:\/\/doi.org\/10.1136\/gutjnl-2020-322082.","journal-title":"Gut"},{"key":"1807_CR36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1136\/gutjnl-2020-322615","volume":"71","author":"S Van Munster","year":"2022","unstructured":"Van Munster S, Nieuwenhuis E, Weusten BLAM, Alvarez Herrero L, Bogte A, Alkhalaf A, et al. Long-term outcomes after endoscopic treatment for Barrett\u2019s neoplasia with radiofrequency ablation\u2009\u00b1\u2009endoscopic resection: results from the national Dutch database in a 10-year period. Gut. 2022;71:265\u201376. https:\/\/doi.org\/10.1136\/gutjnl-2020-322615.","journal-title":"Gut"},{"key":"1807_CR37","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11894-020-00766-2","volume":"22","author":"AE Watts","year":"2020","unstructured":"Watts AE, Cotton CC, Shaheen NJ. Radiofrequency Ablation of Barrett\u2019s Esophagus: Have We Gone Too Far, or Not Far Enough? Curr Gastroenterol Rep. 2020;22:29. https:\/\/doi.org\/10.1007\/s11894-020-00766-2.","journal-title":"Curr Gastroenterol Rep"},{"key":"1807_CR38","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2018.0252","author":"M Barret","year":"2018","unstructured":"Barret M. Diagnosis and treatment of superficial esophageal cancer. Ann Gastroenterol [Internet]. 2018. https:\/\/doi.org\/10.20524\/aog.2018.0252. [cited 2024 Feb 15].","journal-title":"Ann Gastroenterol [Internet]"},{"key":"1807_CR39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/hpb.12097","volume":"16","author":"S Fegrachi","year":"2014","unstructured":"Fegrachi S, Besselink MG, Van Santvoort HC, Van Hillegersberg R, Molenaar IQ. Radiofrequency ablation for unresectable locally advanced pancreatic cancer: a systematic review. HPB. 2014;16:119\u201323. https:\/\/doi.org\/10.1111\/hpb.12097.","journal-title":"HPB"},{"key":"1807_CR40","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.pan.2021.06.005","volume":"21","author":"I Frigerio","year":"2021","unstructured":"Frigerio I, Paiella S, Barbi E, Bianco R, Boz G, Butturini G, et al. Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. Pancreatology. 2021;21:1342\u20138. https:\/\/doi.org\/10.1016\/j.pan.2021.06.005.","journal-title":"Pancreatology"},{"key":"1807_CR41","doi-asserted-by":"publisher","first-page":"E138","DOI":"10.1055\/a-0668-5653","volume":"07","author":"M Barret","year":"2019","unstructured":"Barret M, Leblanc S, Rouquette A, Chaussade S, Terris B, Prat F. EUS-guided pancreatic radiofrequency ablation: preclinical comparison of two currently available devices in a pig model. Endosc Int Open. 2019;07:E138\u201343. https:\/\/doi.org\/10.1055\/a-0668-5653.","journal-title":"Endosc Int Open"},{"key":"1807_CR42","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4103\/eus.eus_28_19","volume":"8","author":"A Larghi","year":"2019","unstructured":"Larghi A, Rizzatti G, Rimba\u015f M, Crino S, Gasbarrini A, Costamagna G. EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat? Endosc Ultrasound. 2019;8:220. https:\/\/doi.org\/10.4103\/eus.eus_28_19.","journal-title":"Endosc Ultrasound"},{"key":"1807_CR43","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1210\/jc.2019-00282","volume":"104","author":"K Oleinikov","year":"2019","unstructured":"Oleinikov K, Dancour A, Epshtein J, Benson A, Mazeh H, Tal I, et al. Endoscopic Ultrasound-Guided Radiofrequency Ablation: A New Therapeutic Approach for Pancreatic Neuroendocrine Tumors. J Clin Endocrinol Metab. 2019;104:2637\u201347. https:\/\/doi.org\/10.1210\/jc.2019-00282.","journal-title":"J Clin Endocrinol Metab"},{"key":"1807_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40425-017-0284-8","volume":"5","author":"R Slovak","year":"2017","unstructured":"Slovak R, Ludwig JM, Gettinger SN, Herbst RS, Kim HS. Immuno-thermal ablations \u2013 boosting the anticancer immune response. J Immunother Cancer. 2017;5:78. https:\/\/doi.org\/10.1186\/s40425-017-0284-8.","journal-title":"J Immunother Cancer"},{"key":"1807_CR45","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.humimm.2009.03.012","volume":"70","author":"AM Fietta","year":"2009","unstructured":"Fietta AM, Morosini M, Passadore I, Cascina A, Draghi P, Dore R, et al. Systemic inflammatory response and downmodulation of peripheral CD25\u2009+\u2009Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Hum Immunol. 2009;70:477\u201386. https:\/\/doi.org\/10.1016\/j.humimm.2009.03.012.","journal-title":"Hum Immunol"},{"key":"1807_CR46","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.amjsurg.2009.12.025","volume":"200","author":"F Ahmad","year":"2010","unstructured":"Ahmad F, Gravante G, Bhardwaj N, Strickland A, Basit R, West K, et al. Changes in interleukin-1\u03b2 and 6 after hepatic microwave tissue ablation compared with radiofrequency, cryotherapy and surgical resections. Am J Surg. 2010;200:500\u20136. https:\/\/doi.org\/10.1016\/j.amjsurg.2009.12.025.","journal-title":"Am J Surg"},{"key":"1807_CR47","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603341","volume":"95","author":"MHMGM Den Brok","year":"2006","unstructured":"Den Brok MHMGM, Sutmuller RPM, Nierkens S, Bennink EJ, Frielink C, Toonen LWJ, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. 2006;95:896\u2013905. https:\/\/doi.org\/10.1038\/sj.bjc.6603341.","journal-title":"Br J Cancer"},{"key":"1807_CR48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12192-011-0261-y","volume":"16","author":"SP Haen","year":"2011","unstructured":"Haen SP, Gouttefangeas C, Schmidt D, Boss A, Clasen S, Von Herbay A, et al. Elevated serum levels of heat shock protein 70 can be detected after radiofrequency ablation. Cell Stress Chaperones. 2011;16:495\u2013504. https:\/\/doi.org\/10.1007\/s12192-011-0261-y.","journal-title":"Cell Stress Chaperones"},{"key":"1807_CR49","doi-asserted-by":"publisher","first-page":"1550342","DOI":"10.1080\/2162402X.2018.1550342","volume":"8","author":"K Lemdani","year":"2019","unstructured":"Lemdani K, Mignet N, Boudy V, Seguin J, Oujagir E, Bawa O, et al. Local immunomodulation combined to radiofrequency ablation results in a complete cure of local and distant colorectal carcinoma. OncoImmunology. 2019;8:1550342. https:\/\/doi.org\/10.1080\/2162402X.2018.1550342.","journal-title":"OncoImmunology"},{"key":"1807_CR50","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3892\/or.2016.4858","volume":"36","author":"J Wan","year":"2016","unstructured":"Wan J, Wu W, Huang Y, Ge W, Liu S. Incomplete radiofrequency ablation accelerates proliferation and angiogenesis of residual lung carcinomas via HSP70\/HIF-1\u03b1. Oncol Rep. 2016;36:659\u201368. https:\/\/doi.org\/10.3892\/or.2016.4858.","journal-title":"Oncol Rep"},{"key":"1807_CR51","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1097\/SLA.0b013e3181a38ef5","volume":"249","author":"MW Nijkamp","year":"2009","unstructured":"Nijkamp MW, Van Der Bilt JDW, De Bruijn MT, Molenaar IQ, Voest EE, Van Diest PJ, et al. Accelerated Perinecrotic Outgrowth of Colorectal Liver Metastases Following Radiofrequency Ablation is a Hypoxia-Driven Phenomenon. Ann Surg. 2009;249:814\u201323. https:\/\/doi.org\/10.1097\/SLA.0b013e3181a38ef5.","journal-title":"Ann Surg"},{"key":"1807_CR52","doi-asserted-by":"publisher","first-page":"175883592095372","DOI":"10.1177\/1758835920953728","volume":"12","author":"S Gao","year":"2020","unstructured":"Gao S, Pu N, Yin H, Li J, Chen Q, Yang M, et al. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. Ther Adv Med Oncol. 2020;12:175883592095372. https:\/\/doi.org\/10.1177\/1758835920953728.","journal-title":"Ther Adv Med Oncol"},{"key":"1807_CR53","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1148\/radiol.15141918","volume":"276","author":"N Rozenblum","year":"2015","unstructured":"Rozenblum N, Zeira E, Bulvik B, Gourevitch S, Yotvat H, Galun E, et al. Radiofrequency Ablation: Inflammatory Changes in the Periablative Zone Can Induce Global Organ Effects, including Liver Regeneration. Radiology. 2015;276:416\u201325. https:\/\/doi.org\/10.1148\/radiol.15141918.","journal-title":"Radiology"},{"key":"1807_CR54","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.3748\/wjg.v12.i23.3716","volume":"12","author":"J H\u00e4nsler","year":"2006","unstructured":"H\u00e4nsler J. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol. 2006;12:3716. https:\/\/doi.org\/10.3748\/wjg.v12.i23.3716.","journal-title":"World J Gastroenterol"},{"key":"1807_CR55","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.32.2.481","author":"C Napoletano","year":"2008","unstructured":"Napoletano C, Taurino F, Biffoni M, De Majo A, Coscarella G, Bellati F, et al. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol [Internet]. 2008. https:\/\/doi.org\/10.3892\/ijo.32.2.481. [cited 2024 Feb 7].","journal-title":"Int J Oncol [Internet]"},{"key":"1807_CR56","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.pan.2017.09.008","volume":"17","author":"A Giardino","year":"2017","unstructured":"Giardino A, Innamorati G, Ugel S, Perbellini O, Girelli R, Frigerio I, et al. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Pancreatology. 2017;17:962\u20136. https:\/\/doi.org\/10.1016\/j.pan.2017.09.008.","journal-title":"Pancreatology"},{"key":"1807_CR57","doi-asserted-by":"publisher","first-page":"S192","DOI":"10.1016\/j.jvir.2010.04.007","volume":"21","author":"MG Lubner","year":"2010","unstructured":"Lubner MG, Brace CL, Hinshaw JL, Lee FT. Microwave Tumor Ablation: Mechanism of Action, Clinical Results, and Devices. J Vasc Interv Radiol. 2010;21:S192\u2013203. https:\/\/doi.org\/10.1016\/j.jvir.2010.04.007.","journal-title":"J Vasc Interv Radiol"},{"key":"1807_CR58","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1615\/CritRevBiomedEng.v38.i1.60","volume":"38","author":"CL Brace","year":"2010","unstructured":"Brace CL. Microwave Tissue Ablation: Biophysics, Technology, and Applications. Crit Rev Biomed Eng. 2010;38:65\u201378. https:\/\/doi.org\/10.1615\/CritRevBiomedEng.v38.i1.60.","journal-title":"Crit Rev Biomed Eng"},{"key":"1807_CR59","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clinimag.2020.06.014","volume":"67","author":"JL McDevitt","year":"2020","unstructured":"McDevitt JL, Collard MD, Murphy RP, Sutphin PD, Yopp AC, Singal AG, et al. Comparison of radiofrequency and microwave ablation and identification of risk factors for primary treatment failure and local progression. Clin Imaging. 2020;67:146\u201351. https:\/\/doi.org\/10.1016\/j.clinimag.2020.06.014.","journal-title":"Clin Imaging"},{"key":"1807_CR60","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.hpb.2018.05.012","volume":"20","author":"H Takahashi","year":"2018","unstructured":"Takahashi H, Kahramangil B, Kose E, Berber E. A comparison of microwave thermosphere versus radiofrequency thermal ablation in the treatment of colorectal liver metastases. HPB. 2018;20:1157\u201362. https:\/\/doi.org\/10.1016\/j.hpb.2018.05.012.","journal-title":"HPB"},{"key":"1807_CR61","doi-asserted-by":"publisher","first-page":"337","DOI":"10.21037\/jgo.2016.09.06","volume":"8","author":"EH Baker","year":"2017","unstructured":"Baker EH, Thompson K, McKillop IH, Cochran A, Kirks R, Vrochides D, et al. Operative microwave ablation for hepatocellular carcinoma: a single center retrospective review of 219 patients. J Gastrointest Oncol. 2017;8:337\u201346. https:\/\/doi.org\/10.21037\/jgo.2016.09.06.","journal-title":"J Gastrointest Oncol"},{"key":"1807_CR62","doi-asserted-by":"publisher","first-page":"28758","DOI":"10.18632\/oncotarget.15672","volume":"8","author":"J Dou","year":"2017","unstructured":"Dou J, Yu J, Yang X, Cheng Z, Han Z, Liu F, et al. Outcomes of microwave ablation for hepatocellular carcinoma adjacent to large vessels: a propensity score analysis. Oncotarget. 2017;8:28758\u201368. https:\/\/doi.org\/10.18632\/oncotarget.15672.","journal-title":"Oncotarget"},{"key":"1807_CR63","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1007\/s00535-005-1671-3","volume":"40","author":"M-D Lu","year":"2005","unstructured":"Lu M-D, Xu H-X, Xie X-Y, Yin X-Y, Chen J-W, Kuang M, et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol. 2005;40:1054\u201360. https:\/\/doi.org\/10.1007\/s00535-005-1671-3.","journal-title":"J Gastroenterol"},{"key":"1807_CR64","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S2468-1253(18)30029-3","volume":"3","author":"N Vietti Violi","year":"2018","unstructured":"Vietti Violi N, Duran R, Guiu B, Cercueil J-P, Aub\u00e9 C, Digklia A, et al. Efficacy of microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with chronic liver disease: a randomised controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2018;3:317\u201325. https:\/\/doi.org\/10.1016\/S2468-1253(18)30029-3.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1807_CR65","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.3390\/jcm12155006","volume":"12","author":"JS Wicks","year":"2023","unstructured":"Wicks JS, Dale BS, Ruffolo L, Pack LJ, Dunne R, Laryea MA, et al. Comparable and Complimentary Modalities for Treatment of Small-Sized HCC: Surgical Resection, Radiofrequency Ablation, and Microwave Ablation. J Clin Med. 2023;12:5006. https:\/\/doi.org\/10.3390\/jcm12155006.","journal-title":"J Clin Med"},{"key":"1807_CR66","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/jso.23849","volume":"111","author":"OS Eng","year":"2015","unstructured":"Eng OS, Tsang AT, Moore D, Chen C, Narayanan S, Gannon CJ, et al. Outcomes of microwave ablation for colorectal cancer liver metastases: A single center experience. J Surg Oncol. 2015;111:410\u20133. https:\/\/doi.org\/10.1002\/jso.23849.","journal-title":"J Surg Oncol"},{"key":"1807_CR67","doi-asserted-by":"publisher","first-page":"51792","DOI":"10.18632\/oncotarget.15244","volume":"8","author":"P Song","year":"2017","unstructured":"Song P, Sheng L, Sun Y, An Y, Guo Y, Zhang Y. The clinical utility and outcomes of microwave ablation for colorectal cancer liver metastases. Oncotarget. 2017;8:51792\u20139. https:\/\/doi.org\/10.18632\/oncotarget.15244.","journal-title":"Oncotarget"},{"key":"1807_CR68","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1245\/s10434-014-3817-0","volume":"21","author":"C Correa-Gallego","year":"2014","unstructured":"Correa-Gallego C, Fong Y, Gonen M, D\u2019Angelica MI, Allen PJ, DeMatteo RP, et al. A Retrospective Comparison of Microwave Ablation vs. Radiofrequency Ablation for Colorectal Cancer Hepatic Metastases. Ann Surg Oncol. 2014;21:4278\u201383. https:\/\/doi.org\/10.1245\/s10434-014-3817-0.","journal-title":"Ann Surg Oncol"},{"key":"1807_CR69","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.diii.2017.07.003","volume":"98","author":"J Palussi\u00e8re","year":"2017","unstructured":"Palussi\u00e8re J, Catena V, Buy X. Percutaneous thermal ablation of lung tumors \u2013 Radiofrequency, microwave and cryotherapy: Where are we going? Diagn Interv Imaging. 2017;98:619\u201325. https:\/\/doi.org\/10.1016\/j.diii.2017.07.003.","journal-title":"Diagn Interv Imaging"},{"key":"1807_CR70","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/1754-9485.12600","volume":"61","author":"CD Ferguson","year":"2017","unstructured":"Ferguson CD, Luis CR, Steinke K. Safety and efficacy of microwave ablation for medically inoperable colorectal pulmonary metastases: Single-centre experience. J Med Imaging Radiat Oncol. 2017;61:243\u20139. https:\/\/doi.org\/10.1111\/1754-9485.12600.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1807_CR71","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s00270-018-2000-6","volume":"41","author":"I Kurilova","year":"2018","unstructured":"Kurilova I, Gonzalez-Aguirre A, Beets-Tan RG, Erinjeri J, Petre EN, Gonen M, et al. Microwave Ablation in the Management of Colorectal Cancer Pulmonary Metastases. Cardiovasc Intervent Radiol. 2018;41:1530\u201344. https:\/\/doi.org\/10.1007\/s00270-018-2000-6.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1807_CR72","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.asjsur.2017.09.005","volume":"42","author":"T Ryu","year":"2019","unstructured":"Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Yoshitomi M, et al. Oncological outcomes after hepatic resection and\/or surgical microwave ablation for liver metastasis from gastric cancer. Asian J Surg. 2019;42:100\u20135. https:\/\/doi.org\/10.1016\/j.asjsur.2017.09.005.","journal-title":"Asian J Surg"},{"key":"1807_CR73","doi-asserted-by":"publisher","unstructured":"Zhou F, Yu X, Liang P, Cheng Z, Han Z-Y, Yu J, et al. Microwave ablation is effective against liver metastases from gastric adenocarcinoma. Int J Hyperth. 2017;1\u20136. https:\/\/doi.org\/10.1080\/02656736.2017.1306120.","DOI":"10.1080\/02656736.2017.1306120"},{"key":"1807_CR74","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/j.1478-3231.2010.02290.x","volume":"30","author":"F Ahmad","year":"2010","unstructured":"Ahmad F, Gravante G, Bhardwaj N, Strickland A, Basit R, West K, et al. Renal effects of microwave ablation compared with radiofrequency, cryotherapy and surgical resection at different volumes of the liver treated: Renal damage after liver ablation. Liver Int. 2010;30:1305\u201314. https:\/\/doi.org\/10.1111\/j.1478-3231.2010.02290.x.","journal-title":"Liver Int"},{"key":"1807_CR75","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/13645706.2017.1286356","volume":"26","author":"H Zhang","year":"2017","unstructured":"Zhang H, Hou X, Cai H, Zhuang X. Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma. Minim Invasive Ther Allied Technol. 2017;26:207\u201311. https:\/\/doi.org\/10.1080\/13645706.2017.1286356.","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"1807_CR76","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00262-020-02734-1","volume":"70","author":"K Leuchte","year":"2021","unstructured":"Leuchte K, Staib E, Thelen M, G\u00f6del P, Lechner A, Zentis P, et al. Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2021;70:893\u2013907. https:\/\/doi.org\/10.1007\/s00262-020-02734-1.","journal-title":"Cancer Immunol Immunother"},{"key":"1807_CR77","doi-asserted-by":"publisher","first-page":"S187","DOI":"10.1016\/j.jvir.2009.12.403","volume":"21","author":"JP Erinjeri","year":"2010","unstructured":"Erinjeri JP, Clark TWI, Cryoablation. Mechanism of Action and Devices. J Vasc Interv Radiol. 2010;21:S187\u201391. https:\/\/doi.org\/10.1016\/j.jvir.2009.12.403.","journal-title":"J Vasc Interv Radiol"},{"key":"1807_CR78","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1002\/hep.27548","volume":"61","author":"C Wang","year":"2015","unstructured":"Wang C, Wang H, Yang W, Hu K, Xie H, Hu K, et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology. 2015;61:1579\u201390. https:\/\/doi.org\/10.1002\/hep.27548.","journal-title":"Hepatology"},{"key":"1807_CR79","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.21873\/anticanres.12997","volume":"38","author":"J Xu","year":"2018","unstructured":"Xu J, Noda C, Erickson A, Mokkarala M, Charalel R, Ramaswamy R, et al. Radiofrequency Ablation vs. Cryoablation for Localized Hepatocellular Carcinoma: A Propensity-matched Population Study. Anticancer Res. 2018;38:6381\u20136. https:\/\/doi.org\/10.21873\/anticanres.12997.","journal-title":"Anticancer Res"},{"key":"1807_CR80","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00330-018-5617-6","volume":"29","author":"R Kim","year":"2019","unstructured":"Kim R, Kang TW, Cha DI, Song KD, Lee MW, Rhim H, et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: Therapeutic efficacy and vascular complications. Eur Radiol. 2019;29:654\u201362. https:\/\/doi.org\/10.1007\/s00330-018-5617-6.","journal-title":"Eur Radiol"},{"key":"1807_CR81","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00261-016-0687-x","volume":"41","author":"PJ Littrup","year":"2016","unstructured":"Littrup PJ, Aoun HD, Adam B, Krycia M, Prus M, Shields A. Percutaneous cryoablation of hepatic tumors: long-term experience of a large U.S. series. Abdom Radiol. 2016;41:767\u201380. https:\/\/doi.org\/10.1007\/s00261-016-0687-x.","journal-title":"Abdom Radiol"},{"key":"1807_CR82","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s00270-010-9868-0","volume":"33","author":"JL Hinshaw","year":"2010","unstructured":"Hinshaw JL, Littrup PJ, Durick N, Leung W, Lee FT, Sampson L, et al. Optimizing the Protocol for Pulmonary Cryoablation: A Comparison of a Dual- and Triple-Freeze Protocol. Cardiovasc Intervent Radiol. 2010;33:1180\u20135. https:\/\/doi.org\/10.1007\/s00270-010-9868-0.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1807_CR83","doi-asserted-by":"publisher","unstructured":"Yamauchi Y, Izumi Y, Kawamura M, Nakatsuka S, Yashiro H, Tsukada N et al. Percutaneous Cryoablation of Pulmonary Metastases from Colorectal Cancer. Marcus AI, editor. PLoS ONE. 2011;6:e27086. https:\/\/doi.org\/10.1371\/journal.pone.0027086","DOI":"10.1371\/journal.pone.0027086"},{"key":"1807_CR84","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1097\/JTO.0000000000000632","volume":"10","author":"T De Baere","year":"2015","unstructured":"De Baere T, Tselikas L, Woodrum D, Abtin F, Littrup P, Deschamps F, et al. Evaluating Cryoablation of Metastatic Lung Tumors in Patients\u2014Safety and Efficacy The ECLIPSE Trial\u2014Interim Analysis at 1 Year. J Thorac Oncol. 2015;10:1468\u201374. https:\/\/doi.org\/10.1097\/JTO.0000000000000632.","journal-title":"J Thorac Oncol"},{"key":"1807_CR85","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1136\/pgmj.2010.098350","volume":"87","author":"J Li","year":"2011","unstructured":"Li J, Chen X, Yang H, Wang X, Yuan D, Zeng Y, et al. Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients. Postgrad Med J. 2011;87:89\u201395. https:\/\/doi.org\/10.1136\/pgmj.2010.098350.","journal-title":"Postgrad Med J"},{"key":"1807_CR86","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/1751-2980.12170","volume":"15","author":"ZG Song","year":"2014","unstructured":"Song ZG, Hao JH, Gao S, Gao CT, Tang Y, Liu JC. The outcome of cryoablation in treating advanced pancreatic cancer: A comparison with palliative bypass surgery alone. J Dig Dis. 2014;15:561\u20139. https:\/\/doi.org\/10.1111\/1751-2980.12170.","journal-title":"J Dig Dis"},{"key":"1807_CR87","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.cryobiol.2012.08.004","volume":"65","author":"L Niu","year":"2012","unstructured":"Niu L, He L, Zhou L, Mu F, Wu B, Li H, et al. Percutaneous ultrasonography and computed tomography guided pancreatic cryoablation: Feasibility and safety assessment. Cryobiology. 2012;65:301\u20137. https:\/\/doi.org\/10.1016\/j.cryobiol.2012.08.004.","journal-title":"Cryobiology"},{"key":"1807_CR88","doi-asserted-by":"crossref","unstructured":"Xu K, Niu L, Mu F, Hu Y. Cryosurgery in combination with brachytherapy of iodine-125 seeds for pancreatic cancer. Gland Surg. 2013;2.","DOI":"10.1142\/9789814329668_0034"},{"key":"1807_CR89","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/02656736.2018.1539253","volume":"36","author":"Q Shao","year":"2019","unstructured":"Shao Q, O\u2019Flanagan S, Lam T, Roy P, Pelaez F, Burbach BJ, et al. Engineering T cell response to cancer antigens by choice of focal therapeutic conditions. Int J Hyperth. 2019;36:130\u20138. https:\/\/doi.org\/10.1080\/02656736.2018.1539253.","journal-title":"Int J Hyperth"},{"key":"1807_CR90","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/00000658-200005000-00016","volume":"231","author":"WC Chapman","year":"2000","unstructured":"Chapman WC, Debelak JP, Wright Pinson C, Washington MK, Atkinson JB, Venkatakrishnan A, et al. Hepatic Cryoablation, But Not Radiofrequency Ablation, Results in Lung Inflammation. Ann Surg. 2000;231:752\u201361. https:\/\/doi.org\/10.1097\/00000658-200005000-00016.","journal-title":"Ann Surg"},{"key":"1807_CR91","unstructured":"Shibata T, Suzuki K, Yamashita T, Takeishi N, Mark M, Hosokawa M. Immunological analysis of enhanced spontaneous metastasis in WKA rats folowing cryosurgery. Anticancer Res. 1998;18(4A):2483\u20132486. https:\/\/europepmc.org\/article\/med\/9703896"},{"key":"1807_CR92","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.cryobiol.2009.10.001","volume":"59","author":"AA Gage","year":"2009","unstructured":"Gage AA, Baust JM, Baust JG. Experimental cryosurgery investigations in vivo. Cryobiology. 2009;59:229\u201343. https:\/\/doi.org\/10.1016\/j.cryobiol.2009.10.001.","journal-title":"Cryobiology"},{"key":"1807_CR93","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/13645706.2017.1310737","volume":"26","author":"H Takaki","year":"2017","unstructured":"Takaki H, Imai N, Thomas CT, Yamakado K, Yarmohammadi H, Ziv E, et al. Changes in peripheral blood T-cell balance after percutaneous tumor ablation. Minim Invasive Ther Allied Technol. 2017;26:331\u20137. https:\/\/doi.org\/10.1080\/13645706.2017.1310737.","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"1807_CR94","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1245\/s10434-009-0846-1","volume":"17","author":"MS Sabel","year":"2010","unstructured":"Sabel MS, Su G, Griffith KA, Chang AE. Rate of Freeze Alters the Immunologic Response After Cryoablation of Breast Cancer. Ann Surg Oncol. 2010;17:1187\u201393. https:\/\/doi.org\/10.1245\/s10434-009-0846-1.","journal-title":"Ann Surg Oncol"},{"key":"1807_CR95","doi-asserted-by":"publisher","first-page":"18229","DOI":"10.1038\/s41598-022-22279-w","volume":"12","author":"M Mauda-Havakuk","year":"2022","unstructured":"Mauda-Havakuk M, Hawken NM, Owen JW, Mikhail AS, Saxena A, Karim B, et al. Comparative analysis of the immune response to RFA and cryoablation in a colon cancer mouse model. Sci Rep. 2022;12:18229. https:\/\/doi.org\/10.1038\/s41598-022-22279-w.","journal-title":"Sci Rep"},{"key":"1807_CR96","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.jvir.2018.07.009","volume":"29","author":"SB White","year":"2018","unstructured":"White SB, Zhang Z, Chen J, Gogineni VR, Larson AC. Early Immunologic Response of Irreversible Electroporation versus Cryoablation in a Rodent Model of Pancreatic Cancer. J Vasc Interv Radiol. 2018;29:1764\u20139. https:\/\/doi.org\/10.1016\/j.jvir.2018.07.009.","journal-title":"J Vasc Interv Radiol"},{"key":"1807_CR97","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/02656730601186138","volume":"23","author":"C Coussios","year":"2007","unstructured":"Ter Haar >Gail, Coussios C. High intensity focused ultrasound: Physical principles and devices. Int J Hyperth. 2007;23:89\u2013104. https:\/\/doi.org\/10.1080\/02656730601186138.","journal-title":"Int J Hyperth"},{"key":"1807_CR98","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00330-008-1137-0","volume":"19","author":"L Zhang","year":"2009","unstructured":"Zhang L, Zhu H, Jin C, Zhou K, Li K, Su H, et al. High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins. Eur Radiol. 2009;19:437\u201345. https:\/\/doi.org\/10.1007\/s00330-008-1137-0.","journal-title":"Eur Radiol"},{"key":"1807_CR99","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/j.ejrad.2009.11.022","volume":"75","author":"K Numata","year":"2010","unstructured":"Numata K, Fukuda H, Ohto M, Itou R, Nozaki A, Kondou M, et al. Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation of hepatocellular carcinoma by three-dimensional sonography with a perflubutane-based contrast agent. Eur J Radiol. 2010;75:e67\u201375. https:\/\/doi.org\/10.1016\/j.ejrad.2009.11.022.","journal-title":"Eur J Radiol"},{"key":"1807_CR100","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/SLA.0b013e3182822c02","volume":"257","author":"ACY Chan","year":"2013","unstructured":"Chan ACY, Cheung TT, Fan ST, Chok KSH, Chan SC, Poon RTP, et al. Survival analysis of high-intensity focused ultrasound therapy versus radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma. Ann Surg. 2013;257:686\u201392. https:\/\/doi.org\/10.1097\/SLA.0b013e3182822c02.","journal-title":"Ann Surg"},{"key":"1807_CR101","doi-asserted-by":"publisher","first-page":"e940","DOI":"10.1259\/bjr\/32750755","volume":"85","author":"J Kim","year":"2012","unstructured":"Kim J, Chung DJ, Jung SE, Cho SH, Hahn S-T, Lee JM. Therapeutic effect of high-intensity focused ultrasound combined with transarterial chemoembolisation for hepatocellular carcinoma\u2009<\u20095\u00a0cm: comparison with transarterial chemoembolisation monotherapy\u2013preliminary observations. Br J Radiol. 2012;85:e940\u2013946. https:\/\/doi.org\/10.1259\/bjr\/32750755.","journal-title":"Br J Radiol"},{"key":"1807_CR102","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/s1499-3872(12)60221-5","volume":"11","author":"TT Cheung","year":"2012","unstructured":"Cheung TT, Chok KSH, Lo RCL, Sharr WW, Chan SC, Poon RTP, et al. High-intensity focused ultrasound ablation as a bridging therapy for hepatocellular carcinoma patients awaiting liver transplantation. Hepatobiliary Pancreat Dis Int HBPD INT. 2012;11:542\u20134. https:\/\/doi.org\/10.1016\/s1499-3872(12)60221-5.","journal-title":"Hepatobiliary Pancreat Dis Int HBPD INT"},{"key":"1807_CR103","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12893-021-01307-y","volume":"21","author":"B Zhou","year":"2021","unstructured":"Zhou B, He N, Hong J, Yang T, Ng DM, Gao X, et al. HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study. BMC Surg. 2021;21:308. https:\/\/doi.org\/10.1186\/s12893-021-01307-y.","journal-title":"BMC Surg"},{"key":"1807_CR104","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1007\/s00464-020-07644-y","volume":"35","author":"T Yang","year":"2021","unstructured":"Yang T, Ng DM, Du N, He N, Dai X, Chen P, et al. HIFU for the treatment of difficult colorectal liver metastases with unsuitable indications for resection and radiofrequency ablation: a phase I clinical trial. Surg Endosc. 2021;35:2306\u201315. https:\/\/doi.org\/10.1007\/s00464-020-07644-y.","journal-title":"Surg Endosc"},{"key":"1807_CR105","doi-asserted-by":"publisher","first-page":"5818","DOI":"10.1007\/s00330-020-07682-z","volume":"31","author":"M Marinova","year":"2021","unstructured":"Marinova M, Feradova H, Gonzalez-Carmona MA, Conrad R, Tonguc T, Thudium M, et al. Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers. Eur Radiol. 2021;31:5818\u201329. https:\/\/doi.org\/10.1007\/s00330-020-07682-z.","journal-title":"Eur Radiol"},{"key":"1807_CR106","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1055\/a-0820-5564","volume":"191","author":"M Marinova","year":"2019","unstructured":"Marinova M, Wilhelm-Buchstab T, Strunk H. Advanced Pancreatic Cancer: High-Intensity Focused Ultrasound (HIFU) and Other Local Ablative Therapies. ROFO Fortschr Geb Rontgenstr Nuklearmed. 2019;191:216\u201327. https:\/\/doi.org\/10.1055\/a-0820-5564.","journal-title":"ROFO Fortschr Geb Rontgenstr Nuklearmed"},{"key":"1807_CR107","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.acra.2007.04.008","volume":"14","author":"W Hundt","year":"2007","unstructured":"Hundt W, O\u2019Connell-Rodwell CE, Bednarski MD, Steinbach S, Guccione S. In vitro effect of focused ultrasound or thermal stress on HSP70 expression and cell viability in three tumor cell lines. Acad Radiol. 2007;14:859\u201370. https:\/\/doi.org\/10.1016\/j.acra.2007.04.008.","journal-title":"Acad Radiol"},{"key":"1807_CR108","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1088\/0031-9155\/53\/13\/017","volume":"53","author":"DE Kruse","year":"2008","unstructured":"Kruse DE, Mackanos MA, O\u2019Connell-Rodwell CE, Contag CH, Ferrara KW. Short-duration-focused ultrasound stimulation of Hsp70 expression in vivo. Phys Med Biol. 2008;53:3641\u201360. https:\/\/doi.org\/10.1088\/0031-9155\/53\/13\/017.","journal-title":"Phys Med Biol"},{"key":"1807_CR109","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ultrasmedbio.2009.12.004","volume":"36","author":"J Deng","year":"2010","unstructured":"Deng J, Zhang Y, Feng J, Wu F. Dendritic cells loaded with ultrasound-ablated tumour induce in vivo specific antitumour immune responses. Ultrasound Med Biol. 2010;36:441\u20138. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2009.12.004.","journal-title":"Ultrasound Med Biol"},{"key":"1807_CR110","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1158\/0008-5472.CAN-03-3949","volume":"64","author":"MHMGM den Brok","year":"2004","unstructured":"den Brok MHMGM, Sutmuller RPM, van der Voort R, Bennink EJ, Figdor CG, Ruers TJM, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64:4024\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3949.","journal-title":"Cancer Res"},{"key":"1807_CR111","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.surg.2008.10.010","volume":"145","author":"P Lu","year":"2009","unstructured":"Lu P, Zhu X-Q, Xu Z-L, Zhou Q, Zhang J, Wu F. Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery. 2009;145:286\u201393. https:\/\/doi.org\/10.1016\/j.surg.2008.10.010.","journal-title":"Surgery"},{"key":"1807_CR112","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ultrasmedbio.2007.07.013","volume":"34","author":"Q Zhou","year":"2008","unstructured":"Zhou Q, Zhu X-Q, Zhang J, Xu Z-L, Lu P, Wu F. Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment. Ultrasound Med Biol. 2008;34:81\u20137. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2007.07.013.","journal-title":"Ultrasound Med Biol"},{"key":"1807_CR113","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/02656736.2021.1900926","volume":"38","author":"T Tonguc","year":"2021","unstructured":"Tonguc T, Strunk H, Gonzalez-Carmona MA, Recker F, L\u00fctjohann D, Thudium M, et al. US-guided high-intensity focused ultrasound (HIFU) of abdominal tumors: outcome, early ablation-related laboratory changes and inflammatory reaction. A single-center experience from Germany. Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2021;38:65\u201374. https:\/\/doi.org\/10.1080\/02656736.2021.1900926.","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"key":"1807_CR114","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/02656736.2015.1007538","volume":"31","author":"VA Khokhlova","year":"2015","unstructured":"Khokhlova VA, Fowlkes JB, Roberts WW, Schade GR, Xu Z, Khokhlova TD, et al. Histotripsy methods in mechanical disintegration of tissue: towards clinical applications. Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2015;31:145\u201362. https:\/\/doi.org\/10.3109\/02656736.2015.1007538.","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"key":"1807_CR115","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1016\/j.ultrasmedbio.2018.07.025","volume":"44","author":"KJ Pahk","year":"2018","unstructured":"Pahk KJ, G\u00e9lat P, Kim H, Saffari N. Bubble dynamics in boiling histotripsy. Ultrasound Med Biol. 2018;44:2673\u201396. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2018.07.025.","journal-title":"Ultrasound Med Biol"},{"key":"1807_CR116","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.ultrasmedbio.2018.10.035","volume":"45","author":"KB Bader","year":"2019","unstructured":"Bader KB, Vlaisavljevich E, Maxwell AD. For Whom the Bubble Grows: Physical Principles of Bubble Nucleation and Dynamics in Histotripsy Ultrasound Therapy. Ultrasound Med Biol. 2019;45:1056\u201380. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2018.10.035.","journal-title":"Ultrasound Med Biol"},{"key":"1807_CR117","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1080\/02656736.2021.1905189","volume":"38","author":"Z Xu","year":"2021","unstructured":"Xu Z, Hall TL, Vlaisavljevich E, Lee FT. Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound. Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2021;38:561\u201375. https:\/\/doi.org\/10.1080\/02656736.2021.1905189.","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"key":"1807_CR118","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.ultrasmedbio.2013.02.005","volume":"39","author":"E Vlaisavljevich","year":"2013","unstructured":"Vlaisavljevich E, Kim Y, Allen S, Owens G, Pelletier S, Cain C, et al. Image-guided non-invasive ultrasound liver ablation using histotripsy: feasibility study in an in vivo porcine model. Ultrasound Med Biol. 2013;39:1398\u2013409. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2013.02.005.","journal-title":"Ultrasound Med Biol"},{"key":"1807_CR119","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/02656736.2022.2112309","volume":"39","author":"J Vidal-Jove","year":"2022","unstructured":"Vidal-Jove J, Serres X, Vlaisavljevich E, Cannata J, Duryea A, Miller R, et al. First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2022;39:1115\u201323. https:\/\/doi.org\/10.1080\/02656736.2022.2112309.","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"key":"1807_CR120","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1109\/TUFFC.2021.3078094","volume":"68","author":"A Hendricks-Wenger","year":"2021","unstructured":"Hendricks-Wenger A, Sereno J, Gannon J, Zeher A, Brock RM, Beitel-White N, et al. Histotripsy Ablation Alters the Tumor Microenvironment and Promotes Immune System Activation in a Subcutaneous Model of Pancreatic Cancer. IEEE Trans Ultrason Ferroelectr Freq Control. 2021;68:2987\u20133000. https:\/\/doi.org\/10.1109\/TUFFC.2021.3078094.","journal-title":"IEEE Trans Ultrason Ferroelectr Freq Control"},{"key":"1807_CR121","doi-asserted-by":"publisher","first-page":"2247187","DOI":"10.1080\/02656736.2023.2247187","volume":"40","author":"J Gannon","year":"2023","unstructured":"Gannon J, Imran KM, Hendricks-Wenger A, Edwards M, Covell H, Ruger L, et al. Ultrasound-guided noninvasive pancreas ablation using histotripsy: feasibility study in an in vivo porcine model. Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2023;40:2247187. https:\/\/doi.org\/10.1080\/02656736.2023.2247187.","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"key":"1807_CR122","doi-asserted-by":"publisher","first-page":"9050","DOI":"10.1038\/s41598-019-45542-z","volume":"9","author":"KJ Pahk","year":"2019","unstructured":"Pahk KJ, Shin C-H, Bae IY, Yang Y, Kim S-H, Pahk K, et al. Boiling Histotripsy-induced Partial Mechanical Ablation Modulates Tumour Microenvironment by Promoting Immunogenic Cell Death of Cancers. Sci Rep. 2019;9:9050. https:\/\/doi.org\/10.1038\/s41598-019-45542-z.","journal-title":"Sci Rep"},{"key":"1807_CR123","doi-asserted-by":"publisher","first-page":"108393","DOI":"10.1016\/j.pharmthera.2023.108393","volume":"244","author":"H Ashar","year":"2023","unstructured":"Ashar H, Ranjan A. Immunomodulation and targeted drug delivery with high intensity focused ultrasound (HIFU): Principles and mechanisms. Pharmacol Ther. 2023;244:108393. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108393.","journal-title":"Pharmacol Ther"},{"key":"1807_CR124","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5946\/ce.2013.46.1.24","volume":"46","author":"RR Allison","year":"2013","unstructured":"Allison RR, Moghissi K. Photodynamic Therapy (PDT): PDT Mechanisms. Clin Endosc. 2013;46:24\u20139. https:\/\/doi.org\/10.5946\/ce.2013.46.1.24.","journal-title":"Clin Endosc"},{"key":"1807_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jphotobiol.2009.04.001","volume":"96","author":"CA Robertson","year":"2009","unstructured":"Robertson CA, Evans DH, Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B. 2009;96:1\u20138. https:\/\/doi.org\/10.1016\/j.jphotobiol.2009.04.001.","journal-title":"J Photochem Photobiol B"},{"key":"1807_CR126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1572-1000(05)00030-X","volume":"2","author":"AP Castano","year":"2005","unstructured":"Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther. 2005;2:1\u201323. https:\/\/doi.org\/10.1016\/S1572-1000(05)00030-X.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1807_CR127","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-1-60761-697-9_3","volume":"635","author":"D Kessel","year":"2010","unstructured":"Kessel D, Oleinick NL. Photodynamic therapy and cell death pathways. Methods Mol Biol Clifton NJ. 2010;635:35\u201346. https:\/\/doi.org\/10.1007\/978-1-60761-697-9_3.","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"1807_CR128","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.biopha.2018.07.049","volume":"106","author":"S Kwiatkowski","year":"2018","unstructured":"Kwiatkowski S, Knap B, Przystupski D, Saczko J, K\u0119dzierska E, Knap-Czop K, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother Biomedecine Pharmacother. 2018;106:1098\u2013107. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.049.","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"1807_CR129","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.gie.2005.06.047","volume":"62","author":"BF Overholt","year":"2005","unstructured":"Overholt BF, Lightdale CJ, Wang KK, Canto MI, Burdick S, Haggitt RC, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett\u2019s esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc. 2005;62:488\u201398. https:\/\/doi.org\/10.1016\/j.gie.2005.06.047.","journal-title":"Gastrointest Endosc"},{"key":"1807_CR130","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11695-015-2010-2","volume":"26","author":"CL Mueller","year":"2016","unstructured":"Mueller CL, Ferri LE. Endoluminal therapies for Barrett\u2019s esophagus. Obes Surg. 2016;26:721\u20136. https:\/\/doi.org\/10.1007\/s11695-015-2010-2.","journal-title":"Obes Surg"},{"key":"1807_CR131","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/lsm.22006","volume":"44","author":"J Lindenmann","year":"2012","unstructured":"Lindenmann J, Matzi V, Neuboeck N, Anegg U, Baumgartner E, Maier A, et al. Individualized, multimodal palliative treatment of inoperable esophageal cancer: Clinical impact of photodynamic therapy resulting in prolonged survival. Lasers Surg Med. 2012;44:189\u201398. https:\/\/doi.org\/10.1002\/lsm.22006.","journal-title":"Lasers Surg Med"},{"key":"1807_CR132","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/den.13353","volume":"31","author":"H Wu","year":"2019","unstructured":"Wu H, Minamide T, Yano T. Role of photodynamic therapy in the treatment of esophageal cancer. Dig Endosc. 2019;31:508\u201316. https:\/\/doi.org\/10.1111\/den.13353.","journal-title":"Dig Endosc"},{"key":"1807_CR133","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.gie.2015.11.016","volume":"83","author":"K Hatogai","year":"2016","unstructured":"Hatogai K, Yano T, Kojima T, Onozawa M, Daiko H, Nomura S, et al. Salvage photodynamic therapy for local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Gastrointest Endosc. 2016;83:1130\u2013e11393. https:\/\/doi.org\/10.1016\/j.gie.2015.11.016.","journal-title":"Gastrointest Endosc"},{"key":"1807_CR134","doi-asserted-by":"publisher","first-page":"22135","DOI":"10.18632\/oncotarget.14029","volume":"8","author":"T Yano","year":"2017","unstructured":"Yano T, Kasai H, Horimatsu T, Yoshimura K, Teramukai S, Morita S, et al. A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer. Oncotarget. 2017;8:22135\u201344. https:\/\/doi.org\/10.18632\/oncotarget.14029.","journal-title":"Oncotarget"},{"key":"1807_CR135","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1111\/php.13206","volume":"96","author":"T Yano","year":"2020","unstructured":"Yano T, Wang KK. Photodynamic Therapy for Gastrointestinal Cancer. Photochem Photobiol. 2020;96:517\u201323. https:\/\/doi.org\/10.1111\/php.13206.","journal-title":"Photochem Photobiol"},{"key":"1807_CR136","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10120-017-0704-y","volume":"21","author":"N Hasuike","year":"2018","unstructured":"Hasuike N, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H, et al. A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2018;21:114\u201323. https:\/\/doi.org\/10.1007\/s10120-017-0704-y.","journal-title":"Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc"},{"key":"1807_CR137","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/s0016-5085(98)70537-2","volume":"114","author":"MA Ortner","year":"1998","unstructured":"Ortner MA, Liebetruth J, Schreiber S, Hanft M, Wruck U, Fusco V, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology. 1998;114:536\u201342. https:\/\/doi.org\/10.1016\/s0016-5085(98)70537-2.","journal-title":"Gastroenterology"},{"key":"1807_CR138","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.pdpdt.2012.03.002","volume":"9","author":"CL Leggett","year":"2012","unstructured":"Leggett CL, Gorospe EC, Murad MH, Montori VM, Baron TH, Wang KK. Photodynamic therapy for unresectable cholangiocarcinoma: a comparative effectiveness systematic review and meta-analyses. Photodiagnosis Photodyn Ther. 2012;9:189\u201395. https:\/\/doi.org\/10.1016\/j.pdpdt.2012.03.002.","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"1807_CR139","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/jso.2930380103","volume":"38","author":"T Schroder","year":"1988","unstructured":"Schroder T, Chen IW, Sperling M, Bell RH, Brackett K, Joffe SN. Hematoporphyrin derivative uptake and photodynamic therapy in pancreatic carcinoma. J Surg Oncol. 1988;38:4\u20139. https:\/\/doi.org\/10.1002\/jso.2930380103.","journal-title":"J Surg Oncol"},{"key":"1807_CR140","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/bjs.1800790826","volume":"79","author":"PT Chatlani","year":"1992","unstructured":"Chatlani PT, Nuutinen PJ, Toda N, Barr H, MacRobert AJ, Bedwell J, et al. Selective necrosis in hamster pancreatic tumours using photodynamic therapy with phthalocyanine photosensitization. Br J Surg. 1992;79:786\u201390. https:\/\/doi.org\/10.1002\/bjs.1800790826.","journal-title":"Br J Surg"},{"key":"1807_CR141","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/bjc.1997.451","volume":"76","author":"P Mikvy","year":"1997","unstructured":"Mikvy P, Messman H, MacRobert AJ, Pauer M, Sams VR, Davies CL, et al. Photodynamic therapy of a transplanted pancreatic cancer model using meta-tetrahydroxyphenylchlorin (mTHPC). Br J Cancer. 1997;76:713\u20138. https:\/\/doi.org\/10.1038\/bjc.1997.451.","journal-title":"Br J Cancer"},{"key":"1807_CR142","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/gut.50.4.549","volume":"50","author":"SG Bown","year":"2002","unstructured":"Bown SG, Rogowska AZ, Whitelaw DE, Lees WR, Lovat LB, Ripley P, et al. Photodynamic therapy for cancer of the pancreas. Gut. 2002;50:549\u201357. https:\/\/doi.org\/10.1136\/gut.50.4.549.","journal-title":"Gut"},{"key":"1807_CR143","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.gie.2018.09.007","volume":"89","author":"JM DeWitt","year":"2019","unstructured":"DeWitt JM, Sandrasegaran K, O\u2019Neil B, House MG, Zyromski NJ, Sehdev A, et al. Phase 1 study of EUS-guided photodynamic therapy for locally advanced pancreatic cancer. Gastrointest Endosc. 2019;89:390\u20138. https:\/\/doi.org\/10.1016\/j.gie.2018.09.007.","journal-title":"Gastrointest Endosc"},{"key":"1807_CR144","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1038\/bjc.2014.95","volume":"110","author":"MT Huggett","year":"2014","unstructured":"Huggett MT, Jermyn M, Gillams A, Illing R, Mosse S, Novelli M, et al. Phase I\/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer. Br J Cancer. 2014;110:1698\u2013704. https:\/\/doi.org\/10.1038\/bjc.2014.95.","journal-title":"Br J Cancer"},{"key":"1807_CR145","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1111\/php.12273","volume":"90","author":"R Biswas","year":"2014","unstructured":"Biswas R, Moon JH, Ahn J. Chlorin e6 Derivative Radachlorin Mainly Accumulates in Mitochondria, Lysosome and Endoplasmic Reticulum and Shows High Affinity toward Tumors in Nude Mice in Photodynamic Therapy. Photochem Photobiol. 2014;90:1108\u201318. https:\/\/doi.org\/10.1111\/php.12273.","journal-title":"Photochem Photobiol"},{"key":"1807_CR146","doi-asserted-by":"publisher","first-page":"e103762","DOI":"10.1371\/journal.pone.0103762","volume":"9","author":"B Kleemann","year":"2014","unstructured":"Kleemann B, Loos B, Scriba TJ, Lang D, Davids LM. AT <>Slominski editor 2014 St John\u2019s Wort (Hypericum perforatum L.) Photomedicine: Hypericin-Photodynamic Therapy Induces Metastatic Melanoma Cell Death. PLoS ONE 9 e103762 https:\/\/doi.org\/10.1371\/journal.pone.0103762.","journal-title":"PLoS ONE"},{"key":"1807_CR147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5411\/wji.v4.i1.1","volume":"4","author":"E Reginato","year":"2014","unstructured":"Reginato E, Wolf P, Hamblin MR. Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects. World J Immunol. 2014;4:1\u201311. https:\/\/doi.org\/10.5411\/wji.v4.i1.1.","journal-title":"World J Immunol"},{"key":"1807_CR148","doi-asserted-by":"publisher","first-page":"47242","DOI":"10.18632\/oncotarget.9725","volume":"7","author":"M Tanaka","year":"2016","unstructured":"Tanaka M, Kataoka H, Yano S, Sawada T, Akashi H, Inoue M, et al. Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin). Oncotarget. 2016;7:47242\u201351. https:\/\/doi.org\/10.18632\/oncotarget.9725.","journal-title":"Oncotarget"},{"key":"1807_CR149","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1148\/radiol.2020192190","volume":"295","author":"B Geboers","year":"2020","unstructured":"Geboers B, Scheffer HJ, Graybill PM, Ruarus AH, Nieuwenhuizen S, Puijk RS, et al. High-Voltage Electrical Pulses in Oncology: Irreversible Electroporation, Electrochemotherapy, Gene Electrotransfer, Electrofusion, and Electroimmunotherapy. Radiology. 2020;295:254\u201372. https:\/\/doi.org\/10.1148\/radiol.2020192190.","journal-title":"Radiology"},{"key":"1807_CR150","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/978-3-319-55113-5_5","volume-title":"Irreversible Electroporation Clin Pract","author":"JA Vogel","year":"2018","unstructured":"Vogel JA, Vroomen LGPH, Srimathveeravalli G. The Effect of Irreversible Electroporation on Blood Vessels, Bile Ducts, Urinary Tract, Intestines, and Nerves. In: Meijerink MR, Scheffer HJ, Narayanan G, editors. Irreversible Electroporation Clin Pract. Cham: Springer International Publishing; 2018. p. 81\u201394. https:\/\/doi.org\/10.1007\/978-3-319-55113-5_5."},{"key":"1807_CR151","doi-asserted-by":"publisher","first-page":"39","DOI":"10.5114\/wo.2016.57815","volume":"20","author":"M Wichtowski","year":"2016","unstructured":"Wichtowski M, Nowaczyk P, Kocur J, Murawa D. Irreversible electroporation in the treatment of locally advanced pancreas and liver metastases of colorectal carcinoma. Contemp Oncol Poznan Pol. 2016;20:39\u201344. https:\/\/doi.org\/10.5114\/wo.2016.57815.","journal-title":"Contemp Oncol Poznan Pol"},{"key":"1807_CR152","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/jso.23280","volume":"107","author":"R Cannon","year":"2013","unstructured":"Cannon R, Ellis S, Hayes D, Narayanan G, Martin RCG. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107:544\u20139. https:\/\/doi.org\/10.1002\/jso.23280.","journal-title":"J Surg Oncol"},{"key":"1807_CR153","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jvir.2010.12.014","volume":"22","author":"KR Thomson","year":"2011","unstructured":"Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol JVIR. 2011;22:611\u201321. https:\/\/doi.org\/10.1016\/j.jvir.2010.12.014.","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"1807_CR154","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1007\/s00330-014-3259-x","volume":"24","author":"HJ Scheffer","year":"2014","unstructured":"Scheffer HJ, Nielsen K, van Tilborg Aa, Vieveen JM, Bouwman JM, Kazemier RA. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study. Eur Radiol. 2014;24:2467\u201375. https:\/\/doi.org\/10.1007\/s00330-014-3259-x.","journal-title":"Eur Radiol"},{"key":"1807_CR155","doi-asserted-by":"publisher","first-page":"e76260","DOI":"10.1371\/journal.pone.0076260","volume":"8","author":"P Philips","year":"2013","unstructured":"Philips P, Hays D, Martin RCG. Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PLoS ONE. 2013;8:e76260. https:\/\/doi.org\/10.1371\/journal.pone.0076260.","journal-title":"PLoS ONE"},{"key":"1807_CR156","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jvir.2014.04.007","volume":"25","author":"PJ Hosein","year":"2014","unstructured":"Hosein PJ, Echenique A, Loaiza-Bonilla A, Froud T, Barbery K, Rocha Lima CM, et al. Percutaneous Irreversible Electroporation for the Treatment of Colorectal Cancer Liver Metastases with a Proposal for a New Response Evaluation System. J Vasc Interv Radiol. 2014;25:1233\u2013e12392. https:\/\/doi.org\/10.1016\/j.jvir.2014.04.007.","journal-title":"J Vasc Interv Radiol"},{"key":"1807_CR157","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1148\/radiol.2021203089","volume":"299","author":"MR Meijerink","year":"2021","unstructured":"Meijerink MR, Ruarus AH, Vroomen LGPH, Puijk RS, Geboers B, Nieuwenhuizen S, et al. Irreversible Electroporation to Treat Unresectable Colorectal Liver Metastases (COLDFIRE-2): A Phase II, Two-Center, Single-Arm Clinical Trial. Radiology. 2021;299:470\u201380. https:\/\/doi.org\/10.1148\/radiol.2021203089.","journal-title":"Radiology"},{"key":"1807_CR158","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s00270-018-2120-z","volume":"42","author":"S Mafeld","year":"2019","unstructured":"Mafeld S, Wong JJ, Kibriya N, Stenberg B, Manas D, Bassett P, et al. Percutaneous Irreversible Electroporation (IRE) of Hepatic Malignancy: A Bi-institutional Analysis of Safety and Outcomes. Cardiovasc Intervent Radiol. 2019;42:577\u201383. https:\/\/doi.org\/10.1007\/s00270-018-2120-z.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"1807_CR159","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jvir.2022.03.024","volume":"33","author":"LC Franken","year":"2022","unstructured":"Franken LC, van Veldhuisen E, Ruarus AH, Coelen RJS, Roos E, van Delden OM, et al. Outcomes of Irreversible Electroporation for Perihilar Cholangiocarcinoma: A Prospective Pilot Study. J Vasc Interv Radiol JVIR. 2022;33:805\u2013e8131. https:\/\/doi.org\/10.1016\/j.jvir.2022.03.024.","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"1807_CR160","doi-asserted-by":"publisher","first-page":"710536","DOI":"10.3389\/fonc.2021.710536","volume":"11","author":"P-C Yang","year":"2021","unstructured":"Yang P-C, Chen Y-J, Li X-Y, Hsiao C-Y, Cheng B-B, Gao Y, et al. Irreversible Electroporation Treatment With Intraoperative Biliary Stenting for Unresectable Perihilar Cholangiocarcinoma: A Pilot Study. Front Oncol. 2021;11:710536. https:\/\/doi.org\/10.3389\/fonc.2021.710536.","journal-title":"Front Oncol"},{"key":"1807_CR161","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/jso.25110","volume":"118","author":"K-W Huang","year":"2018","unstructured":"Huang K-W, Yang P-C, Pua U, Kim M-D, Li S-P, Qiu Y-D, et al. The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma. J Surg Oncol. 2018;118:31\u20136. https:\/\/doi.org\/10.1002\/jso.25110.","journal-title":"J Surg Oncol"},{"key":"1807_CR162","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1097\/SLA.0000000000001441","volume":"262","author":"RCG Martin","year":"2015","unstructured":"Martin RCG, Kwon D, Chalikonda S, Sellers M, Kotz E, Scoggins C, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262:486\u201394. https:\/\/doi.org\/10.1097\/SLA.0000000000001441. discussion 492\u2013494.","journal-title":"Ann Surg"},{"key":"1807_CR163","doi-asserted-by":"publisher","first-page":"275","DOI":"10.21037\/jgo.2018.01.14","volume":"9","author":"E Leen","year":"2018","unstructured":"Leen E, Picard J, Stebbing J, Abel M, Dhillon T, Wasan H. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2018;9:275\u201381. https:\/\/doi.org\/10.21037\/jgo.2018.01.14.","journal-title":"J Gastrointest Oncol"},{"key":"1807_CR164","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1148\/radiol.2019191109","volume":"294","author":"AH Ruarus","year":"2020","unstructured":"Ruarus AH, Vroomen LGPH, Geboers B, van Veldhuisen E, Puijk RS, Nieuwenhuizen S, et al. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. Radiology. 2020;294:212\u201320. https:\/\/doi.org\/10.1148\/radiol.2019191109.","journal-title":"Radiology"},{"key":"1807_CR165","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jamcollsurg.2013.10.013","volume":"218","author":"EM Dunki-Jacobs","year":"2014","unstructured":"Dunki-Jacobs EM, Philips P, Martin RCG. Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas. J Am Coll Surg. 2014;218:179\u201387. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2013.10.013.","journal-title":"J Am Coll Surg"},{"key":"1807_CR166","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11912-021-01057-3","volume":"23","author":"FEF Timmer","year":"2021","unstructured":"Timmer FEF, Geboers B, Nieuwenhuizen S, Schouten EAC, Dijkstra M, De Vries JJJ, et al. Locally Advanced Pancreatic Cancer: Percutaneous Management Using Ablation, Brachytherapy, Intra-arterial Chemotherapy, and Intra-tumoral Immunotherapy. Curr Oncol Rep. 2021;23:68. https:\/\/doi.org\/10.1007\/s11912-021-01057-3.","journal-title":"Curr Oncol Rep"},{"key":"1807_CR167","doi-asserted-by":"publisher","first-page":"15353","DOI":"10.1038\/s41598-021-94583-w","volume":"11","author":"HJ Jeon","year":"2021","unstructured":"Jeon HJ, Choi HS, Keum B, Bang EJ, Lee KW, Kim SH, et al. Feasibility and effectiveness of endoscopic irreversible electroporation for the upper gastrointestinal tract: an experimental animal study. Sci Rep. 2021;11:15353. https:\/\/doi.org\/10.1038\/s41598-021-94583-w.","journal-title":"Sci Rep"},{"key":"1807_CR168","doi-asserted-by":"publisher","first-page":"7917","DOI":"10.1038\/s41598-023-33635-9","volume":"13","author":"HJ Jeon","year":"2023","unstructured":"Jeon HJ, Choi HS, Lee JM, Kim ES, Keum B, Jeen YT, et al. Assessment of efficacy and safety of advanced endoscopic irreversible electroporation catheter in the esophagus. Sci Rep. 2023;13:7917. https:\/\/doi.org\/10.1038\/s41598-023-33635-9.","journal-title":"Sci Rep"},{"key":"1807_CR169","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41467-019-08782-1","volume":"10","author":"J Zhao","year":"2019","unstructured":"Zhao J, Wen X, Tian L, Li T, Xu C, Wen X, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun. 2019;10:899. https:\/\/doi.org\/10.1038\/s41467-019-08782-1.","journal-title":"Nat Commun"},{"key":"1807_CR170","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1245\/s10434-018-07144-3","volume":"26","author":"H Pandit","year":"2019","unstructured":"Pandit H, Hong YK, Li Y, Rostas J, Pulliam Z, Li SP, et al. Evaluating the Regulatory Immunomodulation Effect of Irreversible Electroporation (IRE) in Pancreatic Adenocarcinoma. Ann Surg Oncol. 2019;26:800\u20136. https:\/\/doi.org\/10.1245\/s10434-018-07144-3.","journal-title":"Ann Surg Oncol"},{"key":"1807_CR171","doi-asserted-by":"publisher","first-page":"1652532","DOI":"10.1080\/2162402X.2019.1652532","volume":"8","author":"HJ Scheffer","year":"2019","unstructured":"Scheffer HJ, Stam AGM, Geboers B, Vroomen LGPH, Ruarus A, De Bruijn B, et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. OncoImmunology. 2019;8:1652532. https:\/\/doi.org\/10.1080\/2162402X.2019.1652532.","journal-title":"OncoImmunology"},{"key":"1807_CR172","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s13346-019-00672-9","volume":"10","author":"B Liang","year":"2020","unstructured":"Liang B, Zhao D, Liu Y, Guo X, Zhang H, Zhang L, et al. Chemoembolization of liver cancer with doxorubicin-loaded CalliSpheres microspheres: plasma pharmacokinetics, intratumoral drug concentration, and tumor necrosis in a rabbit model. Drug Deliv Transl Res. 2020;10:185\u201391. https:\/\/doi.org\/10.1007\/s13346-019-00672-9.","journal-title":"Drug Deliv Transl Res"},{"key":"1807_CR173","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ctrv.2018.11.002","volume":"72","author":"J-L Raoul","year":"2019","unstructured":"Raoul J-L, Forner A, Bolondi L, Cheung TT, Kloeckner R, De Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28\u201336. https:\/\/doi.org\/10.1016\/j.ctrv.2018.11.002.","journal-title":"Cancer Treat Rev"},{"key":"1807_CR174","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00384-015-2246-2","volume":"30","author":"W Liu","year":"2015","unstructured":"Liu W, Song Q-K, Xing B-C. A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for colorectal cancer liver metastases. Int J Colorectal Dis. 2015;30:1091\u2013102. https:\/\/doi.org\/10.1007\/s00384-015-2246-2.","journal-title":"Int J Colorectal Dis"},{"key":"1807_CR175","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208\u201336. https:\/\/doi.org\/10.1002\/hep.20933.","journal-title":"Hepatology"},{"key":"1807_CR176","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"J Llovet","year":"2003","unstructured":"Llovet J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37:429\u201342. https:\/\/doi.org\/10.1053\/jhep.2003.50047.","journal-title":"Hepatology"},{"key":"1807_CR177","doi-asserted-by":"publisher","first-page":"113400","DOI":"10.1016\/j.ejca.2023.113400","volume":"195","author":"D Malka","year":"2023","unstructured":"Malka D, Verret B, Faron M, Guimbaud R, Caramella C, Edeline J, et al. Hepatic arterial oxaliplatin plus intravenous 5-fluorouracil and cetuximab for first-line treatment of colorectal liver metastases: A multicenter phase II trial. Eur J Cancer. 2023;195:113400. https:\/\/doi.org\/10.1016\/j.ejca.2023.113400.","journal-title":"Eur J Cancer"},{"key":"1807_CR178","doi-asserted-by":"publisher","first-page":"3465","DOI":"10.1200\/JCO.2008.20.1301","volume":"27","author":"NE Kemeny","year":"2009","unstructured":"Kemeny NE, Melendez FDH, Capanu M, Paty PB, Fong Y, Schwartz LH, et al. Conversion to Resectability Using Hepatic Artery Infusion Plus Systemic Chemotherapy for the Treatment of Unresectable Liver Metastases From Colorectal Carcinoma. J Clin Oncol. 2009;27:3465\u201371. https:\/\/doi.org\/10.1200\/JCO.2008.20.1301.","journal-title":"J Clin Oncol"},{"key":"1807_CR179","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1245\/s10434-007-9581-7","volume":"15","author":"V Boige","year":"2008","unstructured":"Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, et al. Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure. Ann Surg Oncol. 2008;15:219\u201326. https:\/\/doi.org\/10.1245\/s10434-007-9581-7.","journal-title":"Ann Surg Oncol"},{"key":"1807_CR180","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/annonc\/mdv548","volume":"27","author":"FA L\u00e9vi","year":"2016","unstructured":"L\u00e9vi FA, Boige V, Hebbar M, Smith D, Lep\u00e8re C, Focan C, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol. 2016;27:267\u201374. https:\/\/doi.org\/10.1093\/annonc\/mdv548.","journal-title":"Ann Oncol"},{"key":"1807_CR181","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/SLA.0b013e31827b9005","volume":"257","author":"D Go\u00e9r\u00e9","year":"2013","unstructured":"Go\u00e9r\u00e9 D, Benhaim L, Bonnet S, Malka D, Faron M, Elias D, et al. Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases in Patients at High Risk of Hepatic Recurrence: A Comparative Study Between Hepatic Arterial Infusion of Oxaliplatin and Modern Systemic Chemotherapy. Ann Surg. 2013;257:114\u201320. https:\/\/doi.org\/10.1097\/SLA.0b013e31827b9005.","journal-title":"Ann Surg"},{"key":"1807_CR182","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1186\/s12885-018-4697-7","volume":"18","author":"D Go\u00e9r\u00e9","year":"2018","unstructured":"Go\u00e9r\u00e9 D, Pignon J-P, Gelli M, Elias D, Benhaim L, Deschamps F, et al. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II\/III trial - PACHA-01 (NCT02494973). BMC Cancer. 2018;18:787. https:\/\/doi.org\/10.1186\/s12885-018-4697-7.","journal-title":"BMC Cancer"},{"key":"1807_CR183","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12885-020-6571-7","volume":"20","author":"A Boil\u00e8ve","year":"2020","unstructured":"Boil\u00e8ve A, Maillard A, Wagner M, Dromain C, Laurent C, Dupont Bierre E, et al. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30\/PRODIGE 53 (NCT03164655)- study protocol. BMC Cancer. 2020;20:74. https:\/\/doi.org\/10.1186\/s12885-020-6571-7.","journal-title":"BMC Cancer"},{"key":"1807_CR184","first-page":"1387","volume":"32","author":"G Fiorentini","year":"2012","unstructured":"Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32:1387\u201395.","journal-title":"Anticancer Res"},{"key":"1807_CR185","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1002\/cncr.29534","volume":"121","author":"RCG Martin","year":"2015","unstructured":"Martin RCG, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver\u2010limited metastasis. Cancer. 2015;121:3649\u201358. https:\/\/doi.org\/10.1002\/cncr.29534.","journal-title":"Cancer"},{"key":"1807_CR186","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/s41416-020-0917-4","volume":"123","author":"S Pernot","year":"2020","unstructured":"Pernot S, Pellerin O, Artru P, Mont\u00e9rymard C, Smith D, Raoul J-L, et al. Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. Br J Cancer. 2020;123:518\u201324. https:\/\/doi.org\/10.1038\/s41416-020-0917-4.","journal-title":"Br J Cancer"},{"key":"1807_CR187","doi-asserted-by":"publisher","first-page":"e40847","DOI":"10.1371\/journal.pone.0040847","volume":"7","author":"F Liu","year":"2012","unstructured":"Liu F, Tang Y, Sun J, Yuan Z, Li S, Sheng J, et al. Regional intra-arterial vs. systemic chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2012;7:e40847. https:\/\/doi.org\/10.1371\/journal.pone.0040847.","journal-title":"PLoS ONE"},{"key":"1807_CR188","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.pan.2017.11.014","volume":"18","author":"TJ Vogl","year":"2018","unstructured":"Vogl TJ, Mohamed SA, Albrecht MH, Gruber-Roh T, Lin H, Nour Eldin NEA, et al. Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and survival rates. Pancreatology. 2018;18:94\u20139. https:\/\/doi.org\/10.1016\/j.pan.2017.11.014.","journal-title":"Pancreatology"},{"key":"1807_CR189","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/MPA.0b013e318220e5b9","volume":"40","author":"A Azizi","year":"2011","unstructured":"Azizi A, Naguib NNN, Mbalisike E, Farshid P, Emami AH, Vogl TJ. Liver Metastases of Pancreatic Cancer: Role of Repetitive Transarterial Chemoembolization (TACE) on Tumor Response and Survival. Pancreas. 2011;40:1271\u20135. https:\/\/doi.org\/10.1097\/MPA.0b013e318220e5b9.","journal-title":"Pancreas"},{"key":"1807_CR190","doi-asserted-by":"publisher","unstructured":"Liao Y, Wang B, Huang Z-L, Shi M, Yu X-J, Zheng L et al. Increased Circulating Th17 Cells after Transarterial Chemoembolization Correlate with Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective Study. Lee NP, editor. PLoS ONE. 2013;8:e60444. https:\/\/doi.org\/10.1371\/journal.pone.0060444","DOI":"10.1371\/journal.pone.0060444"},{"key":"1807_CR191","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.3892\/mmr.2015.4171","volume":"12","author":"J Liao","year":"2015","unstructured":"Liao J, Xiao J, Zhou Y, Liu Z, Wang C. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. Mol Med Rep. 2015;12:6065\u201371. https:\/\/doi.org\/10.3892\/mmr.2015.4171.","journal-title":"Mol Med Rep"},{"key":"1807_CR192","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cyto.2013.07.021","volume":"64","author":"MJ Kim","year":"2013","unstructured":"Kim MJ, Jang JW, Oh BS, Kwon JH, Chung KW, Jung HS, et al. Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma. Cytokine. 2013;64:516\u201322. https:\/\/doi.org\/10.1016\/j.cyto.2013.07.021.","journal-title":"Cytokine"},{"key":"1807_CR193","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00535-009-0155-2","volume":"45","author":"K Hiroishi","year":"2010","unstructured":"Hiroishi K, Eguchi J, Baba T, Shimazaki T, Ishii S, Hiraide A, et al. Strong CD8\u2009+\u2009T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2010;45:451\u20138. https:\/\/doi.org\/10.1007\/s00535-009-0155-2.","journal-title":"J Gastroenterol"},{"key":"1807_CR194","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/his.14317","volume":"79","author":"A Montasser","year":"2021","unstructured":"Montasser A, Beaufr\u00e8re A, Cauchy F, Bouattour M, Soubrane O, Albuquerque M, et al. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma. Histopathology. 2021;79:36\u201346. https:\/\/doi.org\/10.1111\/his.14317.","journal-title":"Histopathology"},{"key":"1807_CR195","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1055\/s-0041-1735606","volume":"38","author":"G Sivananthan","year":"2021","unstructured":"Sivananthan G, Tabori NE. Principles of Radioembolization. Semin Interv Radiol. 2021;38:393\u20136. https:\/\/doi.org\/10.1055\/s-0041-1735606.","journal-title":"Semin Interv Radiol"},{"key":"1807_CR196","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/JHC.S50359","volume":"3","author":"R Sacco","year":"2016","unstructured":"Sacco R, Conte C, Tumino E, Parisi G, Marceglia S, Metrangolo S, et al. Transarterial radioembolization for hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:25\u20139. https:\/\/doi.org\/10.2147\/JHC.S50359.","journal-title":"J Hepatocell Carcinoma"},{"key":"1807_CR197","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1097\/COC.0b013e3181df0a50","volume":"34","author":"B Sangro","year":"2011","unstructured":"Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol. 2011;34:422\u201331. https:\/\/doi.org\/10.1097\/COC.0b013e3181df0a50.","journal-title":"Am J Clin Oncol"},{"key":"1807_CR198","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatol Baltim Md. 2014;60:192\u2013201. https:\/\/doi.org\/10.1002\/hep.27057.","journal-title":"Hepatol Baltim Md"},{"key":"1807_CR199","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","volume":"151","author":"R Salem","year":"2016","unstructured":"Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;151:1155\u2013e11632. https:\/\/doi.org\/10.1053\/j.gastro.2016.08.029.","journal-title":"Gastroenterology"},{"key":"1807_CR200","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/hep.31819","volume":"74","author":"R Salem","year":"2021","unstructured":"Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatol Baltim Md. 2021;74:2342\u201352. https:\/\/doi.org\/10.1002\/hep.31819.","journal-title":"Hepatol Baltim Md"},{"key":"1807_CR201","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(17)30683-6.","journal-title":"Lancet Oncol"},{"key":"1807_CR202","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1148\/radiol.211806","volume":"303","author":"E Dhondt","year":"2022","unstructured":"Dhondt E, Lambert B, Hermie L, Huyck L, Vanlangenhove P, Geerts A, et al. 90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology. 2022;303:699\u2013710. https:\/\/doi.org\/10.1148\/radiol.211806.","journal-title":"Radiology"},{"key":"1807_CR203","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S1470-2045(17)30457-6","volume":"18","author":"HS Wasan","year":"2017","unstructured":"Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18:1159\u201371. https:\/\/doi.org\/10.1016\/S1470-2045(17)30457-6.","journal-title":"Lancet Oncol"},{"key":"1807_CR204","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1245\/s10434-020-08486-7","volume":"27","author":"D Riby","year":"2020","unstructured":"Riby D, Mazzotta AD, Bergeat D, Verdure L, Sulpice L, Bourien H, et al. Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2020;27:3729\u201337. https:\/\/doi.org\/10.1245\/s10434-020-08486-7.","journal-title":"Ann Surg Oncol"},{"key":"1807_CR205","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","volume":"6","author":"J Edeline","year":"2020","unstructured":"Edeline J, Touchefeu Y, Guiu B, Farge O, Tougeron D, Baumgaertner I, et al. Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2020;6:51\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2019.3702.","journal-title":"JAMA Oncol"},{"key":"1807_CR206","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","volume":"68","author":"V Chew","year":"2019","unstructured":"Chew V, Lee YH, Pan L, Nasir NJM, Lim CJ, Chua C, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 2019;68:335\u201346. https:\/\/doi.org\/10.1136\/gutjnl-2017-315485.","journal-title":"Gut"},{"key":"1807_CR207","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12885-020-6613-1","volume":"20","author":"L Craciun","year":"2020","unstructured":"Craciun L, De Wind R, Demetter P, Lucidi V, Bohlok A, Michiels S, et al. Retrospective analysis of the immunogenic effects of intra-arterial locoregional therapies in hepatocellular carcinoma: a rationale for combining selective internal radiation therapy (SIRT) and immunotherapy. BMC Cancer. 2020;20:135. https:\/\/doi.org\/10.1186\/s12885-020-6613-1.","journal-title":"BMC Cancer"},{"key":"1807_CR208","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2214\/AJR.22.28800","volume":"220","author":"P Torkian","year":"2023","unstructured":"Torkian P, Haghshomar M, Farsad K, Wallace S, Golzarian J, Young SJ. Cancer Immunology: Impact of Radioembolization of Hepatocellular Carcinoma on Immune Response Modulation. AJR Am J Roentgenol. 2023;220:863\u201372. https:\/\/doi.org\/10.2214\/AJR.22.28800.","journal-title":"AJR Am J Roentgenol"},{"key":"1807_CR209","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jvir.2019.05.023","volume":"31","author":"C Zhan","year":"2020","unstructured":"Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, et al. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma. J Vasc Interv Radiol JVIR. 2020;31:25\u201334. https:\/\/doi.org\/10.1016\/j.jvir.2019.05.023.","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"1807_CR210","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.jvir.2020.04.029","volume":"31","author":"DM Ruohoniemi","year":"2020","unstructured":"Ruohoniemi DM, Zhan C, Wei J, Kulkarni K, Aaltonen ET, Horn JC, et al. Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. J Vasc Interv Radiol JVIR. 2020;31:1233\u201341. https:\/\/doi.org\/10.1016\/j.jvir.2020.04.029.","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"1807_CR211","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.clon.2015.02.002","volume":"27","author":"M Dahele","year":"2015","unstructured":"Dahele M, McLaren DB. Stereotactic body radiotherapy. Clin Oncol R Coll Radiol G B. 2015;27:249\u201350. https:\/\/doi.org\/10.1016\/j.clon.2015.02.002.","journal-title":"Clin Oncol R Coll Radiol G B"},{"key":"1807_CR212","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.3390\/curroncol30050382","volume":"30","author":"M Moskalenko","year":"2023","unstructured":"Moskalenko M, Jones BL, Mueller A, Lewis S, Shiao JC, Zakem SJ, et al. Fiducial Markers Allow Accurate and Reproducible Delivery of Liver Stereotactic Body Radiation Therapy. Curr Oncol Tor Ont. 2023;30:5054\u201361. https:\/\/doi.org\/10.3390\/curroncol30050382.","journal-title":"Curr Oncol Tor Ont"},{"key":"1807_CR213","doi-asserted-by":"publisher","first-page":"1061854","DOI":"10.3389\/fonc.2023.1061854","volume":"13","author":"JM Bryant","year":"2023","unstructured":"Bryant JM, Sim AJ, Feygelman V, Latifi K, Rosenberg SA. Adaptive hypofractionted and stereotactic body radiotherapy for lung tumors with real-time MRI guidance. Front Oncol. 2023;13:1061854. https:\/\/doi.org\/10.3389\/fonc.2023.1061854.","journal-title":"Front Oncol"},{"key":"1807_CR214","doi-asserted-by":"publisher","first-page":"20130681","DOI":"10.1259\/bjr.20130681","volume":"87","author":"G Distefano","year":"2014","unstructured":"Distefano G, Baker A, Scott AJD, Webster GJ, UK SABR Consortium Quality Assurance Group. Survey of stereotactic ablative body radiotherapy in the UK by the QA group on behalf of the UK SABR Consortium. Br J Radiol. 2014;87:20130681. https:\/\/doi.org\/10.1259\/bjr.20130681.","journal-title":"Br J Radiol"},{"key":"1807_CR215","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1111\/1754-9485.13309","volume":"65","author":"MD Shanker","year":"2021","unstructured":"Shanker MD, Moodaley P, Soon W, Liu HY, Lee YY, Pryor DI. Stereotactic ablative radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of local control, survival and toxicity outcomes. J Med Imaging Radiat Oncol. 2021;65:956\u201368. https:\/\/doi.org\/10.1111\/1754-9485.13309.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1807_CR216","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","volume":"118","author":"SH Bae","year":"2024","unstructured":"Bae SH, Chun S-J, Chung J-H, Kim E, Kang J-K, Jang WI, et al. Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines. Int J Radiat Oncol Biol Phys. 2024;118:337\u201351. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.08.015.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1807_CR217","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21037\/cco.2020.01.10","volume":"9","author":"M Gil-Raga","year":"2020","unstructured":"Gil-Raga M, Meri-Abad M, Safont Aguilera MJ, Hern\u00e1ndez Machancoses A, Lobo M, Calabuig-Fari\u00f1as S, et al. Long term control stereotactic body radiotherapy (SBRT) for oligometastatic colorectal cancer: a single center study. Chin Clin Oncol. 2020;9:13. https:\/\/doi.org\/10.21037\/cco.2020.01.10.","journal-title":"Chin Clin Oncol"},{"key":"1807_CR218","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","volume":"393","author":"DA Palma","year":"2019","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet Lond Engl. 2019;393:2051\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(18)32487-5.","journal-title":"Lancet Lond Engl"},{"key":"1807_CR219","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.rpor.2020.02.010","volume":"25","author":"A Cacciola","year":"2020","unstructured":"Cacciola A, Parisi S, Tamburella C, Lillo S, Ferini G, Molino L, et al. Stereotactic body radiation therapy and radiofrequency ablation for the treatment of liver metastases: How and when? Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol. 2020;25:299\u2013306. https:\/\/doi.org\/10.1016\/j.rpor.2020.02.010.","journal-title":"Rep Pract Oncol Radiother J Gt Cancer Cent Poznan Pol Soc Radiat Oncol"},{"key":"1807_CR220","doi-asserted-by":"publisher","first-page":"1611456","DOI":"10.3389\/pore.2023.1611456","volume":"29","author":"K Kisivan","year":"2023","unstructured":"Kisivan K, Farkas A, Kovacs P, Glavak C, Lukacs G, Mahr K, et al. Pancreatic SABR using peritumoral fiducials, triggered imaging and breath-hold. Pathol Oncol Res POR. 2023;29:1611456. https:\/\/doi.org\/10.3389\/pore.2023.1611456.","journal-title":"Pathol Oncol Res POR"},{"key":"1807_CR221","doi-asserted-by":"publisher","first-page":"662205","DOI":"10.3389\/fonc.2021.662205","volume":"11","author":"G Rossi","year":"2021","unstructured":"Rossi G, Simoni N, Paiella S, Rossi R, Venezia M, Micera R, et al. Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. Front Oncol. 2021;11:662205. https:\/\/doi.org\/10.3389\/fonc.2021.662205.","journal-title":"Front Oncol"},{"key":"1807_CR222","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.clon.2019.04.006","volume":"31","author":"D Xing","year":"2019","unstructured":"Xing D, Siva S, Hanna GG. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool\u2019s Gold or El Dorado? Clin Oncol. 2019;31:432\u201343. https:\/\/doi.org\/10.1016\/j.clon.2019.04.006.","journal-title":"Clin Oncol"},{"key":"1807_CR223","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13:1050\u20139. https:\/\/doi.org\/10.1038\/nm1622.","journal-title":"Nat Med"},{"key":"1807_CR224","doi-asserted-by":"publisher","first-page":"860","DOI":"10.3390\/cancers11060860","volume":"11","author":"J Boustani","year":"2019","unstructured":"Boustani J, Grapin M, Laurent P-A, Apetoh L, Mirjolet C. The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. Cancers. 2019;11:860. https:\/\/doi.org\/10.3390\/cancers11060860.","journal-title":"Cancers"},{"key":"1807_CR225","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3389\/fimmu.2017.00229","volume":"8","author":"E Wennerberg","year":"2017","unstructured":"Wennerberg E, Lhuillier C, Vanpouille-Box C, Pilones KA, Garc\u00eda-Mart\u00ednez E, Rudqvist N-P, et al. Barriers to Radiation-Induced In Situ Tumor Vaccination. Front Immunol. 2017;8:229. https:\/\/doi.org\/10.3389\/fimmu.2017.00229.","journal-title":"Front Immunol"},{"key":"1807_CR226","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","volume":"3","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, et al. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res. 2015;3:345\u201355. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0196.","journal-title":"Cancer Immunol Res"},{"key":"1807_CR227","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG. Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498\u2013509. https:\/\/doi.org\/10.1016\/S1470-2045(15)00007-8.","journal-title":"Lancet Oncol"},{"key":"1807_CR228","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.hoc.2019.08.011","volume":"33","author":"SJ Otter","year":"2019","unstructured":"Otter SJ, Stewart AJ, Devlin PM. Modern Brachytherapy. Hematol Oncol Clin North Am. 2019;33:1011\u201325. https:\/\/doi.org\/10.1016\/j.hoc.2019.08.011.","journal-title":"Hematol Oncol Clin North Am"},{"key":"1807_CR229","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11912-017-0561-1","volume":"19","author":"S Gottumukkala","year":"2017","unstructured":"Gottumukkala S, Tumati V, Hrycushko B, Folkert M. Endoluminal and Interstitial Brachytherapy for the Treatment of Gastrointestinal Malignancies: a Systematic Review. Curr Oncol Rep. 2017;19:2. https:\/\/doi.org\/10.1007\/s11912-017-0561-1.","journal-title":"Curr Oncol Rep"},{"key":"1807_CR230","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<988::AID-CNCR7>3.0.CO;2-U","volume":"88","author":"LE Gaspar","year":"2000","unstructured":"Gaspar LE, Winter K, Kocha WI, Coia LR, Herskovic A, Graham M. A phase I\/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer. 2000;88:988\u201395.","journal-title":"Cancer"},{"key":"1807_CR231","doi-asserted-by":"publisher","unstructured":"Gaspar LE, Nag S, Herskovic A, Mantravadi R, Speiser B. American Brachytherapy Society (ABS) consensus guidelines for brachytherapy of esophageal cancer. Clinical Research Committee, American Brachytherapy Society, Philadelphia, PA. Int J Radiat Oncol Biol Phys. 1997;38:127\u201332. https:\/\/doi.org\/10.1016\/s0360-3016(97)00231-9","DOI":"10.1016\/s0360-3016(97)00231-9"},{"key":"1807_CR232","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.brachy.2015.02.392","volume":"14","author":"S Wong Hee Kam","year":"2015","unstructured":"Wong Hee Kam S, Rivera S, Hennequin C, Louren\u00e7o N, Chirica M, Munoz-Bongrand N, et al. Salvage high-dose-rate brachytherapy for esophageal cancer in previously irradiated patients: A retrospective analysis. Brachytherapy. 2015;14:531\u20136. https:\/\/doi.org\/10.1016\/j.brachy.2015.02.392.","journal-title":"Brachytherapy"},{"key":"1807_CR233","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/00130404-200201000-00013","volume":"8","author":"JJ Lu","year":"2002","unstructured":"Lu JJ, Bains YS, Abdel-Wahab M, Brandon AH, Wolfson AH, Raub WA, et al. High-dose-rate remote afterloading intracavitary brachytherapy for the treatment of extrahepatic biliary duct carcinoma. Cancer J Sudbury Mass. 2002;8:74\u20138. https:\/\/doi.org\/10.1097\/00130404-200201000-00013.","journal-title":"Cancer J Sudbury Mass"},{"key":"1807_CR234","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/s0009-9260(85)80242-7","volume":"36","author":"J Karani","year":"1985","unstructured":"Karani J, Fletcher M, Brinkley D, Dawson JL, Williams R, Nunnerley H. Internal biliary drainage and local radiotherapy with iridium-192 wire in treatment of hilar cholangiocarcinoma. Clin Radiol. 1985;36:603\u20136. https:\/\/doi.org\/10.1016\/s0009-9260(85)80242-7.","journal-title":"Clin Radiol"},{"key":"1807_CR235","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.3748\/wjg.v10.i23.3506","volume":"10","author":"Y Chen","year":"2004","unstructured":"Chen Y, Wang X-L, Yan Z-P, Cheng J-M, Wang J-H, Gong G-Q, et al. HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice. World J Gastroenterol. 2004;10:3506\u201310. https:\/\/doi.org\/10.3748\/wjg.v10.i23.3506.","journal-title":"World J Gastroenterol"},{"key":"1807_CR236","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ejrad.2007.01.037","volume":"62","author":"V V\u00e1lek","year":"2007","unstructured":"V\u00e1lek V, Kysela P, Kala Z, Kiss I, Tom\u00e1sek J, Petera J. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomised study. Eur J Radiol. 2007;62:175\u20139. https:\/\/doi.org\/10.1016\/j.ejrad.2007.01.037.","journal-title":"Eur J Radiol"},{"key":"1807_CR237","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2214\/ajr.147.2.275","volume":"147","author":"A Dritschilo","year":"1986","unstructured":"Dritschilo A, Grant EG, Harter KW, Holt RW, Rustgi SN, Rodgers JE. Interstitial radiation therapy for hepatic metastases: sonographic guidance for applicator placement. AJR Am J Roentgenol. 1986;147:275\u20138. https:\/\/doi.org\/10.2214\/ajr.147.2.275.","journal-title":"AJR Am J Roentgenol"},{"key":"1807_CR238","doi-asserted-by":"publisher","first-page":"70","DOI":"10.5114\/jcb.2013.36175","volume":"5","author":"DN Sharma","year":"2013","unstructured":"Sharma DN, Thulkar S, Sharma S, Gandhi AK, Haresh KP, Gupta S, et al. High-dose-rate interstitial brachytherapy for liver metastases: first study from India. J Contemp Brachytherapy. 2013;5:70\u20135. https:\/\/doi.org\/10.5114\/jcb.2013.36175.","journal-title":"J Contemp Brachytherapy"},{"key":"1807_CR239","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.radonc.2011.03.005","volume":"100","author":"G Wieners","year":"2011","unstructured":"Wieners G, Mohnike K, Peters N, Bischoff J, Kleine-Tebbe A, Seidensticker R, et al. Treatment of hepatic metastases of breast cancer with CT-guided interstitial brachytherapy - a phase II-study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2011;100:314\u20139. https:\/\/doi.org\/10.1016\/j.radonc.2011.03.005.","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"1807_CR240","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1097\/01.RVI.0000141343.43441.06","volume":"15","author":"J Ricke","year":"2004","unstructured":"Ricke J, Wust P, Wieners G, Beck A, Cho CH, Seidensticker M, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Interv Radiol JVIR. 2004;15:1279\u201386. https:\/\/doi.org\/10.1097\/01.RVI.0000141343.43441.06.","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"1807_CR241","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ijrobp.2009.07.1700","volume":"78","author":"K Mohnike","year":"2010","unstructured":"Mohnike K, Wieners G, Schwartz F, Seidensticker M, Pech M, Ruehl R, et al. Computed tomography-guided high-dose-rate brachytherapy in hepatocellular carcinoma: safety, efficacy, and effect on survival. Int J Radiat Oncol Biol Phys. 2010;78:172\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.07.1700.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1807_CR242","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ijrobp.2009.09.026","volume":"78","author":"J Ricke","year":"2010","unstructured":"Ricke J, Mohnike K, Pech M, Seidensticker M, R\u00fchl R, Wieners G, et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;78:479\u201385. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.09.026.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1807_CR243","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.semradonc.2011.05.005","volume":"21","author":"J Ricke","year":"2011","unstructured":"Ricke J, Wust P. Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol. 2011;21:287\u201393. https:\/\/doi.org\/10.1016\/j.semradonc.2011.05.005.","journal-title":"Semin Radiat Oncol"},{"key":"1807_CR244","doi-asserted-by":"publisher","first-page":"e509","DOI":"10.1016\/j.ejrad.2013.04.046","volume":"82","author":"F Collettini","year":"2013","unstructured":"Collettini F, Singh A, Schnapauff D, Powerski MJ, Denecke T, Wust P, et al. Computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of metastases adjacent to the liver hilum. Eur J Radiol. 2013;82:e509\u2013514. https:\/\/doi.org\/10.1016\/j.ejrad.2013.04.046.","journal-title":"Eur J Radiol"},{"key":"1807_CR245","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.3748\/wjg.v16.i40.5104","volume":"16","author":"Y-P Zou","year":"2010","unstructured":"Zou Y-P, Li W-M, Zheng F, Li F-C, Huang H, Du J-D, et al. Intraoperative radiofrequency ablation combined with 125 iodine seed implantation for unresectable pancreatic cancer. World J Gastroenterol. 2010;16:5104\u201310. https:\/\/doi.org\/10.3748\/wjg.v16.i40.5104.","journal-title":"World J Gastroenterol"},{"key":"1807_CR246","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.12998\/wjcc.v8.i17.3743","volume":"8","author":"C-G Li","year":"2020","unstructured":"Li C-G, Zhou Z-P, Jia Y-Z, Tan X-L, Song Y-Y. Radioactive 125I seed implantation for locally advanced pancreatic cancer: A retrospective analysis of 50 cases. World J Clin Cases. 2020;8:3743\u201350. https:\/\/doi.org\/10.12998\/wjcc.v8.i17.3743.","journal-title":"World J Clin Cases"},{"key":"1807_CR247","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11596-016-1567-x","volume":"36","author":"Y-F Li","year":"2016","unstructured":"Li Y-F, Liu Z-Q, Zhang Y-S, Dong L-M, Wang C-Y, Gou S-M, et al. Implantation of radioactive (125)I seeds improves the prognosis of locally advanced pancreatic cancer patients: A retrospective study. J Huazhong Univ Sci Technol Med Sci Hua Zhong Ke Ji Xue Xue Bao Yi Xue Ying Wen Ban Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban. 2016;36:205\u201310. https:\/\/doi.org\/10.1007\/s11596-016-1567-x.","journal-title":"J Huazhong Univ Sci Technol Med Sci Hua Zhong Ke Ji Xue Xue Bao Yi Xue Ying Wen Ban Huazhong Keji Daxue Xuebao Yixue Yingdewen Ban"},{"key":"1807_CR248","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1756-9966-32-106","volume":"32","author":"H Wang","year":"2013","unstructured":"Wang H, Wang J, Jiang Y, Li J, Tian S, Ran W, et al. The investigation of 125I seed implantation as a salvage modality for unresectable pancreatic carcinoma. J Exp Clin Cancer Res CR. 2013;32:106. https:\/\/doi.org\/10.1186\/1756-9966-32-106.","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"Suppl 2","key":"1807_CR249","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.4103\/0019-509X.172517","volume":"52","author":"B Liu","year":"2015","unstructured":"Liu B, Zhou T, Geng J, Zhang F, Wang J, Li Y. Percutaneous computed tomography-guided iodine-125 seeds implantation for unresectable pancreatic cancer. Indian J Cancer. 2015;52(Suppl 2):e69\u201374. https:\/\/doi.org\/10.4103\/0019-509X.172517.","journal-title":"Indian J Cancer"},{"key":"1807_CR250","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1007\/s00330-009-1703-0","volume":"20","author":"W Zhongmin","year":"2010","unstructured":"Zhongmin W, Yu L, Fenju L, Kemin C, Gang H. Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer. Eur Radiol. 2010;20:1786\u201391. https:\/\/doi.org\/10.1007\/s00330-009-1703-0.","journal-title":"Eur Radiol"},{"key":"1807_CR251","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.brachy.2016.05.004","volume":"15","author":"M Yang","year":"2016","unstructured":"Yang M, Yan Z, Luo J, Liu Q, Zhang W, Ma J, et al. A pilot study of intraluminal brachytherapy using 125I seed strand for locally advanced pancreatic ductal adenocarcinoma with obstructive jaundice. Brachytherapy. 2016;15:859\u201364. https:\/\/doi.org\/10.1016\/j.brachy.2016.05.004.","journal-title":"Brachytherapy"},{"key":"1807_CR252","doi-asserted-by":"publisher","first-page":"e9535","DOI":"10.1097\/MD.0000000000009535","volume":"96","author":"W-F Lv","year":"2017","unstructured":"Lv W-F, Lu D, Xiao J-K, Mukhiya G, Tan Z-X, Cheng D-L, et al. The side effects and complications of percutaneous iodine-125 seeds implantation under CT-guide for patients with advanced pancreatic cancer. Med (Baltim). 2017;96:e9535. https:\/\/doi.org\/10.1097\/MD.0000000000009535.","journal-title":"Med (Baltim)"},{"key":"1807_CR253","doi-asserted-by":"publisher","first-page":"100356","DOI":"10.1016\/j.esmoop.2021.100356","volume":"7","author":"PJ Ross","year":"2022","unstructured":"Ross PJ, Wasan HS, Croagh D, Nikfarjam M, Nguyen N, Aghmesheh M, et al. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine\/nab-paclitaxel or FOLFIRINOX chemotherapy. ESMO Open. 2022;7:100356. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100356.","journal-title":"ESMO Open"},{"key":"1807_CR254","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.dld.2017.05.011","volume":"49","author":"L Moureau-Zabotto","year":"2017","unstructured":"Moureau-Zabotto L, Vendrely V, Abramowitz L, Borg C, Francois E, Goere D, et al. Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Dig Liver Dis. 2017;49:831\u201340. https:\/\/doi.org\/10.1016\/j.dld.2017.05.011.","journal-title":"Dig Liver Dis"},{"key":"1807_CR255","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","volume":"30","author":"D Peiffert","year":"2012","unstructured":"Peiffert D, Tournier-Rangeard L, G\u00e9rard J-P, Lemanski C, Fran\u00e7ois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:1941\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.35.4837.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1807_CR256","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.ijrobp.2010.02.055","volume":"80","author":"J-M Hannoun-Levi","year":"2011","unstructured":"Hannoun-Levi J-M, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, et al. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). Int J Radiat Oncol Biol Phys. 2011;80:712\u201320. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.02.055.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1807_CR257","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1016\/j.ijrobp.2012.09.034","volume":"85","author":"L Moureau-Zabotto","year":"2013","unstructured":"Moureau-Zabotto L, Ortholan C, Hannoun-Levi J-M, Teissier E, Cowen D, Salem N, et al. Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study). Int J Radiat Oncol Biol Phys. 2013;85:e135\u2013142. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.09.034.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1807_CR258","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.canrad.2021.04.006","volume":"25","author":"J-P G\u00e9rard","year":"2021","unstructured":"G\u00e9rard J-P, Barbet N, Dejean C, Montagne L, B\u00e9n\u00e9zery K, Coquard R, et al. Contact X-ray brachytherapy for rectal cancer: Past, present, and future. Cancer Radiother J Soc Francaise Radiother Oncol. 2021;25:795\u2013800. https:\/\/doi.org\/10.1016\/j.canrad.2021.04.006.","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol"},{"key":"1807_CR259","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1016\/j.ijrobp.2011.12.002","volume":"83","author":"C Ortholan","year":"2012","unstructured":"Ortholan C, Romestaing P, Chapet O, Gerard JP. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96\u2009\u2013\u200902 randomized trial. Int J Radiat Oncol Biol Phys. 2012;83:e165\u2013171. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.002.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1807_CR260","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2468-1253(22)00392-2","volume":"8","author":"J-P Gerard","year":"2023","unstructured":"Gerard J-P, Barbet N, Schiappa R, Magn\u00e9 N, Martel I, Mineur L, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2\u2013cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8:356\u201367. https:\/\/doi.org\/10.1016\/S2468-1253(22)00392-2.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1807_CR261","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.annonc.2024.10.827","volume":"36","author":"D Baron","year":"2025","unstructured":"Baron D, Pace Loscos T, Schiappa R, Barbet N, Dost E, Ben Dhia S, et al. A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial. Ann Oncol Off J Eur Soc Med Oncol. 2025;36:208\u201315. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.827.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1807_CR262","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/1097-0142","volume":"39","author":"SE Order","year":"1977","unstructured":"Order SE. The effects of therapeutic irradiation on lymphocytes and immunity. Cancer. 1977;39:737\u201343. https:\/\/doi.org\/10.1002\/1097-0142. (197702)39:2+%3C737::aid-cncr2820390708%3E3.0.co;2-m.","journal-title":"Cancer"},{"key":"1807_CR263","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.brachy.2018.07.004","volume":"17","author":"RB Patel","year":"2018","unstructured":"Patel RB, Baniel CC, Sriramaneni RN, Bradley K, Markovina S, Morris ZS. Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. Brachytherapy. 2018;17:995\u20131003. https:\/\/doi.org\/10.1016\/j.brachy.2018.07.004.","journal-title":"Brachytherapy"},{"key":"1807_CR264","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s12029-023-00927-2","volume":"54","author":"J El Hajj","year":"2023","unstructured":"El Hajj J, Reddy S, Verma N, Huang EH, Kazmi SM. Immune Checkpoint Inhibitors in pMMR\/MSS Colorectal Cancer. J Gastrointest Cancer. 2023;54:1017\u201330. https:\/\/doi.org\/10.1007\/s12029-023-00927-2.","journal-title":"J Gastrointest Cancer"},{"key":"1807_CR265","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1746-1596-7-156","volume":"7","author":"M-A Allard","year":"2012","unstructured":"Allard M-A, Bachet JB, Beauchet A, Julie C, Malafosse R, Penna C, et al. Linear quantification of lymphoid infiltration of the tumor margin: a reproducible method, developed with colorectal cancer tissues, for assessing a highly variable prognostic factor. Diagn Pathol. 2012;7:156. https:\/\/doi.org\/10.1186\/1746-1596-7-156.","journal-title":"Diagn Pathol"},{"key":"1807_CR266","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18:197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007-y.","journal-title":"Nat Rev Drug Discov"},{"key":"1807_CR267","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-019-0272-7","volume":"17","author":"O Kepp","year":"2020","unstructured":"Kepp O, Marabelle A, Zitvogel L, Kroemer G. Oncolysis without viruses \u2014 inducing systemic anticancer immune responses with local therapies. Nat Rev Clin Oncol. 2020;17:49\u201364. https:\/\/doi.org\/10.1038\/s41571-019-0272-7.","journal-title":"Nat Rev Clin Oncol"},{"key":"1807_CR268","doi-asserted-by":"publisher","first-page":"1118845","DOI":"10.3389\/fimmu.2023.1118845","volume":"14","author":"NJ Kim","year":"2023","unstructured":"Kim NJ, Yoon JH, Tuomi AC, Lee J, Kim D. In-situ tumor vaccination by percutaneous ablative therapy and its synergy with immunotherapeutics: An update on combination therapy. Front Immunol. 2023;14:1118845. https:\/\/doi.org\/10.3389\/fimmu.2023.1118845.","journal-title":"Front Immunol"},{"key":"1807_CR269","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2023.41.4_suppl.141","volume":"41","author":"JF Seligmann","year":"2023","unstructured":"Seligmann JF, Kossler T, Mauer M, Evrard S, Gootjes EC, Freedman J, et al. Durvalumab and tremelimumab plus local tumor ablation (RFA or stereotactic radiotherapy) in patients with metastatic colorectal cancer with unresectable liver metastases: Results of the EORTC-1560-GITCG (ILOC) phase II study. J Clin Oncol. 2023;41:141\u2013141. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.141.","journal-title":"J Clin Oncol"},{"key":"1807_CR270","doi-asserted-by":"publisher","first-page":"188526","DOI":"10.1016\/j.bbcan.2021.188526","volume":"1875","author":"E De Lombaerde","year":"2021","unstructured":"De Lombaerde E, De Wever O, De Geest BG. Delivery routes matter: Safety and efficacy of intratumoral immunotherapy. Biochim Biophys Acta BBA - Rev Cancer. 2021;1875:188526. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188526.","journal-title":"Biochim Biophys Acta BBA - Rev Cancer"},{"key":"1807_CR271","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JGO.19.00142","volume":"5","author":"A Renner","year":"2019","unstructured":"Renner A, Burotto M, Rojas C. Immune Checkpoint Inhibitor Dosing: Can We Go Lower Without Compromising Clinical Efficacy? J Glob Oncol. 2019;5:1\u20135. https:\/\/doi.org\/10.1200\/JGO.19.00142.","journal-title":"J Glob Oncol"},{"key":"1807_CR272","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-021-00507-y","volume":"18","author":"I Melero","year":"2021","unstructured":"Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol. 2021;18:558\u201376. https:\/\/doi.org\/10.1038\/s41571-021-00507-y.","journal-title":"Nat Rev Clin Oncol"},{"key":"1807_CR273","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-019-0568-2","volume":"7","author":"MA Aznar","year":"2019","unstructured":"Aznar MA, Planelles L, Perez-Olivares M, Molina C, Garasa S, Etxeberr\u00eda I, et al. Immunotherapeutic effects of intratumoral nanoplexed poly I:C. J Immunother Cancer. 2019;7:116. https:\/\/doi.org\/10.1186\/s40425-019-0568-2.","journal-title":"J Immunother Cancer"},{"key":"1807_CR274","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1016\/j.celrep.2017.05.015","volume":"19","author":"Y Takeda","year":"2017","unstructured":"Takeda Y, Kataoka K, Yamagishi J, Ogawa S, Seya T, Matsumoto M. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy. Cell Rep. 2017;19:1874\u201387. https:\/\/doi.org\/10.1016\/j.celrep.2017.05.015.","journal-title":"Cell Rep"},{"key":"1807_CR275","doi-asserted-by":"publisher","first-page":"1984677","DOI":"10.1080\/2162402X.2021.1984677","volume":"10","author":"J Humeau","year":"2021","unstructured":"Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. Trial watch: intratumoral immunotherapy. Oncoimmunology. 2021;10:1984677. https:\/\/doi.org\/10.1080\/2162402X.2021.1984677.","journal-title":"Oncoimmunology"},{"key":"1807_CR276","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1586\/14737140.2015.1115725","volume":"15","author":"KJ Harrington","year":"2015","unstructured":"Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015;15:1389\u2013403. https:\/\/doi.org\/10.1586\/14737140.2015.1115725.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1807_CR277","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1158\/2326-6066.CIR-19-0101","volume":"7","author":"JSS Narayanan","year":"2019","unstructured":"Narayanan JSS, Ray P, Hayashi T, Whisenant TC, Vicente D, Carson DA, et al. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model. Cancer Immunol Res. 2019;7:1714\u201326. https:\/\/doi.org\/10.1158\/2326-6066.CIR-19-0101.","journal-title":"Cancer Immunol Res"},{"key":"1807_CR278","doi-asserted-by":"publisher","first-page":"218074","DOI":"10.1016\/j.canlet.2025.218074","volume":"634","author":"DK Ledezma","year":"2025","unstructured":"Ledezma DK, Joshi U, Nguyen-Ta K, Sonowal H, Russo H, Newton IG, et al. Irreversible electroporation with intratumoral plant virus immunotherapy induces systemic immunity in a metastatic model of pancreatic cancer. Cancer Lett. 2025;634:218074. https:\/\/doi.org\/10.1016\/j.canlet.2025.218074.","journal-title":"Cancer Lett"},{"key":"1807_CR279","doi-asserted-by":"publisher","first-page":"118421","DOI":"10.1016\/j.ijpharm.2019.06.012","volume":"567","author":"K Lemdani","year":"2019","unstructured":"Lemdani K, Seguin J, Lesieur C, Al Sabbagh C, Doan B-T, Richard C, et al. Mucoadhesive thermosensitive hydrogel for the intra-tumoral delivery of immunomodulatory agents, in vivo evidence of adhesion by means of non-invasive imaging techniques. Int J Pharm. 2019;567:118421. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.06.012.","journal-title":"Int J Pharm"},{"key":"1807_CR280","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3390\/pharmaceutics16030315","volume":"16","author":"J Seguin","year":"2024","unstructured":"Seguin J, El Hajjam M, Legagneux J, Diakhaby S, Mignet N, Boudy V, et al. Radiofrequency Combined with Intratumoral Immunotherapy: Preclinical Results and Safety in Metastatic Colorectal Carcinoma. Pharmaceutics. 2024;16:315. https:\/\/doi.org\/10.3390\/pharmaceutics16030315.","journal-title":"Pharmaceutics"},{"key":"1807_CR281","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/gutjnl-2014-308286","volume":"65","author":"B Behm","year":"2016","unstructured":"Behm B, Di Fazio P, Michl P, Neureiter D, Kemmerling R, Hahn EG, et al. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut. 2016;65:134\u201343. https:\/\/doi.org\/10.1136\/gutjnl-2014-308286.","journal-title":"Gut"},{"key":"1807_CR282","doi-asserted-by":"publisher","first-page":"e2301848","DOI":"10.1002\/adhm.202301848","volume":"13","author":"A Som","year":"2024","unstructured":"Som A, Rosenboom J-G, Wehrenberg-Klee E, Chandler A, Ndakwah G, Chen E, et al. Percutaneous Intratumoral Immunoadjuvant Gel Increases the Abscopal Effect of Cryoablation for Checkpoint Inhibitor Resistant Cancer. Adv Healthc Mater. 2024;13:e2301848. https:\/\/doi.org\/10.1002\/adhm.202301848.","journal-title":"Adv Healthc Mater"},{"key":"1807_CR283","doi-asserted-by":"publisher","first-page":"398","DOI":"10.37349\/etat.2022.00090","volume":"3","author":"HD Do","year":"2022","unstructured":"Do HD, Marie C, Bessoles S, Dhotel H, Seguin J, Larrat B, et al. Combination of thermal ablation by focused ultrasound, pFAR4-IL-12 transfection and lipidic adjuvant provide a distal immune response. Explor Target Anti-Tumor Ther. 2022;3:398\u2013413. https:\/\/doi.org\/10.37349\/etat.2022.00090.","journal-title":"Explor Target Anti-Tumor Ther"},{"key":"1807_CR284","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1158\/1078-0432.CCR-05-1986","volume":"12","author":"H Saji","year":"2006","unstructured":"Saji H, Song W, Furumoto K, Kato H, Engleman EG. Systemic antitumor effect of intratumoral injection of dendritic cells in combination with local photodynamic therapy. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12:2568\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1986.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1807_CR285","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.jvir.2019.02.023","volume":"30","author":"I Vivas","year":"2019","unstructured":"Vivas I, Iribarren K, Lozano T, Cano D, Lasarte-Cia A, Chocarro S, et al. Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma. J Vasc Interv Radiol JVIR. 2019;30:1098\u2013105. https:\/\/doi.org\/10.1016\/j.jvir.2019.02.023.","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"1807_CR286","doi-asserted-by":"publisher","first-page":"8852233","DOI":"10.1155\/2021\/8852233","volume":"2021","author":"A Lasarte-Cia","year":"2021","unstructured":"Lasarte-Cia A, Lozano T, Cano D, Mart\u00edn-Otal C, Navarro F, Gorraiz M, et al. Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma. BioMed Res Int. 2021;2021:8852233. https:\/\/doi.org\/10.1155\/2021\/8852233.","journal-title":"BioMed Res Int"},{"key":"1807_CR287","doi-asserted-by":"publisher","first-page":"100777","DOI":"10.1016\/j.tranon.2020.100777","volume":"13","author":"M Kitahara","year":"2020","unstructured":"Kitahara M, Mizukoshi E, Terashima T, Nakagawa H, Horii R, Iida N, et al. Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation. Transl Oncol. 2020;13:100777. https:\/\/doi.org\/10.1016\/j.tranon.2020.100777.","journal-title":"Transl Oncol"},{"key":"1807_CR288","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1158\/1078-0432.CCR-09-0110","volume":"15","author":"EE Johnson","year":"2009","unstructured":"Johnson EE, Yamane BH, Buhtoiarov IN, Lum HD, Rakhmilevich AL, Mahvi DM, et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:4875\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0110.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1807_CR289","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00262-013-1514-7","volume":"63","author":"H Nakagawa","year":"2014","unstructured":"Nakagawa H, Mizukoshi E, Iida N, Terashima T, Kitahara M, Marukawa Y, et al. In vivo immunological antitumor effect of OK-432-stimulated dendritic cell transfer after radiofrequency ablation. Cancer Immunol Immunother CII. 2014;63:347\u201356. https:\/\/doi.org\/10.1007\/s00262-013-1514-7.","journal-title":"Cancer Immunol Immunother CII"},{"key":"1807_CR290","doi-asserted-by":"publisher","first-page":"e96539","DOI":"10.1371\/journal.pone.0096539","volume":"9","author":"S-G Zheng","year":"2014","unstructured":"Zheng S-G, Xu H-X, Guo L-H, Liu L-N, Lu F. The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: a study in vivo. PLoS ONE. 2014;9:e96539. https:\/\/doi.org\/10.1371\/journal.pone.0096539.","journal-title":"PLoS ONE"},{"key":"1807_CR291","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1080\/02656730902976807","volume":"25","author":"Z Chen","year":"2009","unstructured":"Chen Z, Shen S, Peng B, Tao J. Intratumoural GM-CSF microspheres and CTLA-4 blockade enhance the antitumour immunity induced by thermal ablation in a subcutaneous murine hepatoma model. Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group. 2009;25:374\u201382. https:\/\/doi.org\/10.1080\/02656730902976807.","journal-title":"Int J Hyperth Off J Eur Soc Hyperthermic Oncol North Am Hyperth Group"},{"key":"1807_CR292","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.3892\/etm.2017.5633","volume":"15","author":"H Wu","year":"2018","unstructured":"Wu H, Chen B, Peng B. Effects of intratumoral injection of immunoactivator after microwave ablation on antitumor immunity in a mouse model of hepatocellular carcinoma. Exp Ther Med. 2018;15:1914\u20137. https:\/\/doi.org\/10.3892\/etm.2017.5633.","journal-title":"Exp Ther Med"},{"key":"1807_CR293","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jvir.2023.03.016","volume":"34","author":"MA Ghani","year":"2023","unstructured":"Ghani MA, Bangar A, Yang Y, Jung E, Sauceda C, Mandt T, et al. Treatment of Hepatocellular Carcinoma by Multimodal In Situ Vaccination Using Cryoablation and a Plant Virus Immunostimulant. J Vasc Interv Radiol JVIR. 2023;34:1247\u2013e12578. https:\/\/doi.org\/10.1016\/j.jvir.2023.03.016.","journal-title":"J Vasc Interv Radiol JVIR"},{"key":"1807_CR294","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.3390\/cancers15082210","volume":"15","author":"MR Vrabel","year":"2023","unstructured":"Vrabel MR, Schulman JA, Gillam FB, Mantooth SM, Nguyen KG, Zaharoff DA. Focal Cryo-Immunotherapy with Intratumoral IL-12 Prevents Recurrence of Large Murine Tumors. Cancers. 2023;15:2210. https:\/\/doi.org\/10.3390\/cancers15082210.","journal-title":"Cancers"},{"key":"1807_CR295","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.canlet.2020.12.018","volume":"502","author":"S Sun","year":"2021","unstructured":"Sun S, Liu Y, He C, Hu W, Liu W, Huang X, et al. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Cancer Lett. 2021;502:9\u201324. https:\/\/doi.org\/10.1016\/j.canlet.2020.12.018.","journal-title":"Cancer Lett"},{"key":"1807_CR296","doi-asserted-by":"publisher","first-page":"e006133","DOI":"10.1136\/jitc-2022-006133","volume":"11","author":"JS Shankara Narayanan","year":"2023","unstructured":"Shankara Narayanan JS, Hayashi T, Erdem S, McArdle S, Tiriac H, Ray P, et al. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model. J Immunother Cancer. 2023;11:e006133. https:\/\/doi.org\/10.1136\/jitc-2022-006133.","journal-title":"J Immunother Cancer"},{"key":"1807_CR297","doi-asserted-by":"publisher","first-page":"e2300906","DOI":"10.1002\/adhm.202300906","volume":"12","author":"H Kim","year":"2023","unstructured":"Kim H, Choi B, Mouli SK, Choi H, Harris KR, Kulik LM, et al. Preclinical Development and Validation of Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemo-Immuno-Embolization for the Treatment of Hepatocellular Carcinoma. Adv Healthc Mater. 2023;12:e2300906. https:\/\/doi.org\/10.1002\/adhm.202300906.","journal-title":"Adv Healthc Mater"},{"key":"1807_CR298","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.3389\/fimmu.2018.02030","volume":"9","author":"S Yasmin-Karim","year":"2018","unstructured":"Yasmin-Karim S, Bruck PT, Moreau M, Kunjachan S, Chen GZ, Kumar R, et al. Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer. Front Immunol. 2018;9:2030. https:\/\/doi.org\/10.3389\/fimmu.2018.02030.","journal-title":"Front Immunol"},{"key":"1807_CR299","doi-asserted-by":"publisher","first-page":"464","DOI":"10.4143\/crt.2018.186","volume":"51","author":"CW Choi","year":"2019","unstructured":"Choi CW, Jeong MH, Park Y-S, Son C-H, Lee H-R, Koh E-K. Combination Treatment of Stereotactic Body Radiation Therapy and Immature Dendritic Cell Vaccination for Augmentation of Local and Systemic Effects. Cancer Res Treat. 2019;51:464\u201373. https:\/\/doi.org\/10.4143\/crt.2018.186.","journal-title":"Cancer Res Treat"},{"key":"1807_CR300","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3390\/pharmaceutics13020206","volume":"13","author":"BN Aldosari","year":"2021","unstructured":"Aldosari BN, Alfagih IM, Almurshedi AS. Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines. Pharmaceutics. 2021;13:206. https:\/\/doi.org\/10.3390\/pharmaceutics13020206.","journal-title":"Pharmaceutics"},{"key":"1807_CR301","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/pharmaceutics13010045","volume":"13","author":"IM Alfagih","year":"2020","unstructured":"Alfagih IM, Aldosari B, AlQuadeib B, Almurshedi A, Alfagih MM. Nanoparticles as Adjuvants and Nanodelivery Systems for mRNA-Based Vaccines. Pharmaceutics. 2020;13:45. https:\/\/doi.org\/10.3390\/pharmaceutics13010045.","journal-title":"Pharmaceutics"},{"key":"1807_CR302","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jconrel.2019.06.017","volume":"307","author":"AI Matos","year":"2019","unstructured":"Matos AI, Carreira B, Peres C, Moura LIF, Conniot J, Fourniols T, et al. Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. J Controlled Release. 2019;307:108\u201338. https:\/\/doi.org\/10.1016\/j.jconrel.2019.06.017.","journal-title":"J Controlled Release"},{"key":"1807_CR303","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","volume":"19","author":"S Nooraei","year":"2021","unstructured":"Nooraei S, Bahrulolum H, Hoseini ZS, Katalani C, Hajizade A, Easton AJ, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnol. 2021;19:59. https:\/\/doi.org\/10.1186\/s12951-021-00806-7.","journal-title":"J Nanobiotechnol"},{"key":"1807_CR304","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.addr.2021.03.001","volume":"172","author":"C Peres","year":"2021","unstructured":"Peres C, Matos AI, Moura LIF, Ac\u00farcio RC, Carreira B, Pozzi S, et al. Preclinical models and technologies to advance nanovaccine development. Adv Drug Deliv Rev. 2021;172:148\u201382. https:\/\/doi.org\/10.1016\/j.addr.2021.03.001.","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01807-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-026-01807-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-026-01807-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T06:18:38Z","timestamp":1783059518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-026-01807-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":304,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1007\/s11912-026-01807-1","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"6 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"A.S., J.S, K.L, S.D, C.C, M.E.H, F.P and N.M report no conflicts of interest. F.R. and R.M., regarding activities related to the present article, are no remunerated consultants for Imisca and ClinSearch, and report no other conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the result","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}